Protocol VX14- 661-111, Version  4.0 Page 3 of 69 
Vertex Pharmaceuticals Incorporated   2 PROTOCOL SYNOPSIS  
Title A Phase 2, Randomized, Double -blind, Placebo -controlled, Parallel -group, 
Exploratory Study to Evaluate Effects of VX -661 in Combination With Ivacaftor 
on Lung and Extrapulmonary Systems in Subjects Aged 18 Years and Older With 
Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation 
  
Clinical Phase and 
Clinical Study Type Phase 2, efficacy and safety  
  
Objective  To evaluate the clinical mechanisms of action in lung and extrapulmonary systems 
of VX-661 in combination with ivacaftor (IVA) (VX -661/IVA) in subjects with 
cystic fibrosis (CF) who are homozygous for the F508del mutation on the CF 
transmembrane conductance regulator (CFTR) gene. 
  
Endpoints  Key Endpoints:  
‚Ä¢ Absolute change in percent predicted forced expi[INVESTIGATOR_3741] 1  second 
(ppFEV 1) from baseline at Day  28 
‚Ä¢ Absolute change in mucociliary clearance (MCC) from baseline at Day  28 
‚Ä¢ Absolute change in gastrointestinal pH from baseline at Day  29 
‚Ä¢ Absolute change in sweat chloride from baseline at Day  29 
Other Endpoints:  
  
  
‚Ä¢ Safety and tolerability assessments based on adverse events (AEs), clinical 
laboratory values (i.e., serum chemistry, vitamin levels, lipid panel, hematology, coagulation studies, and urinalysis), standard 12- lead 
electrocardiograms (ECGs), vital signs, and pulse oximetry  
  
Number of Subjects  A target of approximately 35 subjects and up to approximately 45 subjects  
  
Study Population  Male and female subjects aged 18  years and older with CF, homozygous for the 
F508del-CFTR mutation 
Investigational Drug  Active substances:  VX-661/IVA (fixed -dose combination [FDC] with VX -661 
and IVA)  
 Activity: CFTR corrector (VX -661) and potentiator  (IVA) (increased chloride ion 
[Cl‚àí] secretion)  
 Strength and Route of Administration:  100-mg VX-661/150-mg IVA FDC 
film-coated tablet for oral administration  
 Dose Administered: 100-mg VX-661/150-mg IVA daily (qd) 
(1 √ó 100-mg/150-mg FDC tablet qd) in the morning  
 Active substance:  IVA 

Protocol VX14- 661-111, Version  4.0 Page 4 of 69 
Vertex Pharmaceuticals Incorporated    Activity: CFTR potentiator (increased Cl‚àí secretion)  
 Strength and Route of Administration:  150-mg IVA film -coated tablet for oral 
administration  
 Dose Administered:  150-mg IVA qd (1  √ó 150-mg tablet qd) in the evenin g 
  
 VX-661/IVA FDC placebo and IVA placebo  
 Strength and Route of Administration:  0-mg, film-coated, matching placebo 
tablets for oral administration  
  
Study Duration  Excluding the Screening Period (up to 28 days in duration), subjects will 
participate in this study for up to 57  ¬± 7 days. 
During the Treatment Period, study drug (VX -661/IVA or placebo) will be 
administered for 29 ¬± 3 days. A Safety Follow -Up Visit is required for all subjects 
28 ¬± [ADDRESS_1153640] dose of study drug.  
  
Study Design  This is a Phase  2, randomized, double -blind, placebo -controlled, parallel -group, 
multicenter, exploratory study in subjects with CF who are homozygous for the 
F508del-CFTR mutation.  
This study includes a Screening Period, a Treatment Period, and a Safety Follow -
up Visit. 
Screening Period (Day  ‚àí28 through Day ‚àí1): 
The Screening Period will occur between [ADDRESS_1153641] dose of 
study drug to confirm that the subjects meet the eligibility criteria.  
 
During the Screening Period, a patency capsule and a wireless motility capsule 
(WMC) will be administered.  The patency capsule will be administered at the 
Day -[ADDRESS_1153642] will occur 2 days after 
administration of the patency capsule to confirm the pa ssage of the capsule in the 
stool (unless the subject confirms the passage of the capsule prior to the scheduled telephone contact). Subjects who are unable to successfully pass the patency 
capsule test will not be randomized.  
 
The WMC will be  administered  at the Day -[ADDRESS_1153643] will occur 5 
days after administration of the WMC to confirm the passage of the capsule (unless the subject confirms the passage of the caps ule prior to the scheduled 
telephone contact). The subject will not be randomized in the study until passage 
of the WMC has been confirmed by [CONTACT_831231] X -ray, regardless of 
confirmation of passage by [CONTACT_831232].  
Treatment Period (Day  1 through Day 29 ¬± 3 days): 
On Day 1, subjects will be randomized (4:1) to VX -661/IVA combination therapy 
(100-mg VX-661 qd/150- mg IVA every 12 hours [q12h]) or placebo  
Safety Follow -up Visit (28  ¬± [ADDRESS_1153644] dose of study drug)  
The Safety Follow -up Visit is required for all subjects 28  ¬± [ADDRESS_1153645] 
dose of study drug. Subjects who complete the Day  29 Visit and subsequently the 
Safety Follow -up Visit will be offered the opportunity to enroll into an extension 
study of V X-661/IVA combination therapy if they meet eligibility requirements 
for the extension study.  

Protocol VX14- 661-111, Version  4.0 Page 6 of 69 
Vertex Pharmaceuticals Incorporated   3 SCHEDULE OF ASSESSME NTS 
Schedules of Assessments are shown in Table 3-1 (Screening Period) and Table 3-2 (Treatment Period through the Safety Follow-up 
Visit). 
All visits are to be scheduled relative to the Day  1 Visit (first dose of study drug). 
Table 3-1 Study VX14 -661-111: Screening Period  
Assessment  Screening Period  
Day -[ADDRESS_1153646] 5  Days 
After WMC Administration  
Clinic visit  X  Xb  
Informed consent  X    
Inclusion/exclusion criteria review  Continuous from signing of informed consent form (ICF) before randomizationa 
Demographics  X    
Medical history  X    
Ophthalmologic history  X    
CF genotypec X    
Weight, heightd X    
Complete physical examination  X    
Ophthalmologic examinatione Between signing of ICF and randomization  
Standard [ADDRESS_1153647] baseline assessments are performed on Day  -23 through Day  -10 
(Table 3-1), and the remaining are performed on Day 1 ( Table 3-2). Before any baseline assessments are performed, eligibility for enrollment based on all available screening 
assessment results must be verif ied by [CONTACT_093].  
b This visit may occur on 1 day or on 2 separate days (see Section  8.1.1). 
c All subjects will be tested for CFTR genotype regardless of availability of a previous CFTR genotype laboratory report. Refer to the Laboratory Manual for specific 
instructions.  
d Weight and height will be measured with shoes off.  
e One ophthalmologic examination will be conducted by a licensed ophthalmologist during the Screening Period. The ophthalmologic examination does not need to be repeated 
if there is documentation of an examination that met the protocol criteria and that was conducted within 3 months before the Screening Period (see Section 11.7.7). Subjects 
with clinically significant cataracts, lens opacity, Y -suture, or lamellar rings will be excluded.  
f A standard 12-lead ECG will be performed after the subject has been supi[INVESTIGATOR_1919] [ADDRESS_1153648] heart rate (e.g., blood sampling).  

Protocol VX14- 661-111, Version  4.0 Page 7 of 69 
Vertex Pharmaceuticals Incorporated   Table 3-1 Study VX14 -661-111: Screening Period  
Assessment  Screening Period  
Day -[ADDRESS_1153649] 5  Days 
After WMC Administration  
Pulse oximetryg X    
Spi[INVESTIGATOR_831204]  X    
Serum FSHj (postmenopausal female 
subjects only)  X    
Pregnancy testk Serum  Urinel   
Sweat chloridem X    
Hematology  X    
Coagulation  X    
Serum chemistry  X    
Patency capsule  Xn Confirm passageo   
Meal or snack at site    Xp  
WMCq   Xr confirm passages  g Vital signs and pulse oximetry will be co llected after the subject has been at rest (seated or supi[INVESTIGATOR_050]) for 5  minutes. Vital signs will be performed after ECGs and before blood 
sampling.  
h Spi[INVESTIGATOR_14438] - or postbronchodilator (see Section 11.4.1).  
i Spi[INVESTIGATOR_831205], on the same day as the MCC assessment, and prior to both WMC and MCC if bot h are done on the same day. Spi[INVESTIGATOR_831206] ‚â•30 percent predicted FEV1 before MCC (see Section 11.4.2). 
j FSH will be measured for any suspected postmenopausal female with at least [ADDRESS_1153650] be ‚â•40 mIU/mL to 
be considered postmenopausal.  
k Pregnancy tests will be performed for all female subjects of childbearing potential (see Section 11.7.5). 
l Pregnancy test results will be obtained before administration of WMC and the MCC assessment. If the Clinic Visit Day -[ADDRESS_1153651] will occur 2 days after administration of the patency capsule to confirm passage of the patency capsule in the stool (unless the subject confirms passage of 
the capsule prior to the scheduled telephone contact [ Section 11.4.3]). A subject must pass the patency capsule test to continue the Screening Period assessments. If passage of 
the patency capsule is not confirmed during the telephone contact, the medical monitor must  be contact[CONTACT_831233] (see the Study 
Reference Manual for additional information).  
p Subjects must adhere to study restrictions in Table 9-2 regarding meals. During the Clinic Visit(s) on Day  -[ADDRESS_1153652] for 8 hours (water is permitted) 
before administration of a snack bar (in place of the morning meal), and for an additional 4 hours immedia tely following administration of the WMC. ). If  the Day  -23 to ‚Äì 10 
Visit occurs on 2 separate days, a meal or snack bar will be provided at the clinic on both days . 

Protocol VX14- 661-111, Version  4.0 Page 8 of 69 
Vertex Pharmaceuticals Incorporated   Table 3-1 Study VX14 -661-111: Screening Period  
Assessment  Screening Period  
Day -[ADDRESS_1153653]   X  
  
Prior and concomitant medications  Continuous from signing of ICF through Safety Follow -up Visit 
Adverse events  Continuous from signing of ICF through Safety Follow -up Visit 
CF: cystic fibrosis; ECG: electrocardiogram; FSH: follicle -stimulating hormone; MCC: mucociliary clearance; WMC: wireless motility capsule   q If MCC and WMC administration occur on a single day, WMC administration should be completed before the MCC assessment.  
r Subjects must pass the patency capsule test and adhere to WMC restrictions in  Table 9-1 before administration of the WMC (see Section 11.4.3). Subjects will fast for 8 hours 
(water is permitted) before administration of a snack bar (in place of the morning meal) with the WMC, and will fast for an add itional [ADDRESS_1153654] will occur 5  days after the administration of the WMC to evaluate passage of the capsule (unless the subject confirms the passage of the capsule prior to the 
scheduled contact).  If passage of the WMC is not confirmed during the telephone contact, the medical monitor must be contact[CONTACT_831234]. Subjects will not be randomized in the study until passage of the WMC has been confirmed by [CONTACT_831231] X -ray, regardless of confirmation of passage by 
[CONTACT_831235] (see Section 11.4.3 and the Study Reference Manual for additional information).  
t Bronchodilator usage is restricted for [ADDRESS_1153655] MCC scan will be immediately following radiolabeled aerosol inhalation, and the second 
scan 6 hours (¬±  30 minutes) after inhalation. Subjects will adhere to study restrictions in Table 9-1 related to MCC (see the Study Reference Manual for additional 
information).  
  

Protocol VX14- 661-111, Version 4.0 Page 9 of 69 
Vertex Pharmaceuticals Incorporated   Table 3-2 Study VX14 -661-111: Treatment Period and Safety Follow- Up Visit 
Event/Assessmenta  Treatment Period  Telephone Contact 
5 Days After WMC 
Administration  Early  
Treatment 
Terminationb 
Visit Safety Follow -up Visit 
28 (¬± 7) Days 
After Last Dose of 
Study Drug  Day 1 
 Day 14 
(¬± 3 days) Day 28 
(¬± 3 days)c Day 29 
(¬± 3 days) 
Clinic visit  X   Xd X   X X 
Telephone contact   [INVESTIGATOR_331008]   X   
Inclusion and exclusion criteria reviewf X       
Weight and Heightg X  X   X (weight)  X 
Complete physical examinationh X        X 
Standard [ADDRESS_1153656] prematurely discontinues study treatment, an Early Treatment Termination (ETT) Visit should be scheduled as soon as possible after the last dose of study drug. 
Subjects who prematurely discontinue treatment will also be required to complete the Safety Follow -up Visit, approximately 28 (¬± 7) days after their last dose of study drug. 
If the ETT Visit occurs [ADDRESS_1153657] dose of study drug, then the ETT will not be required (see Section 8.1.4). 
c This visit may occur on 1 day or on 2 separate days (see Section 8.1.2). All assessments of the Day  [ADDRESS_1153658] will occur on Day 14 to review adverse events (AEs) and concomitant medications.  
f Confirmation of subject eligibility will occur before randomization.  
g Weight and height will be measured before dosing with shoes off. Height will be collected only for subjects [ADDRESS_1153659] heart rate (e.g., blo od sampling). Subjects must be supi[INVESTIGATOR_1919] 
5 minutes before the start of the ECG.  
j At the Day  1 and Day  29 Visits, ECGs will be collected before dosing and at 1.5 (approximately ¬±  15 minutes) and 3  hours (approximately ¬±  15 minutes) after the morning 
dose of study drug. ECGs collected on Day  [ADDRESS_1153660] ered on the Day of the visit (i.e.,  because of study drug 
interruption or permanent discontinuation of study drug), only [ADDRESS_1153661] (seated or supi[INVESTIGATOR_050]) for at least 5  minutes. Vital signs will be performed after 
ECGs and before blood sampling. In cases where Day  28 Visit assessments occur on 2 separate days, vital signs and pulse oximetry will be collected on both days.  
l Spi[INVESTIGATOR_831207] (see Section 11.4.1). At the Day  28 Visit, bronchodilator usage is 
restricted for 12 hours before the MCC assessment. If the Day  28 Visit assessments occur on 2 separate days, spi[INVESTIGATOR_831208].  

Protocol VX14- 661-111, Version 4.0 Page 10 of 69 
Vertex Pharmaceuticals Incorporated   Table 3-2 Study VX14 -661-111: Treatment Period and Safety Follow- Up Visit 
Event/Assessmenta  Treatment Period  Telephone Contact 
5 Days After WMC 
Administration  Early  
Treatment 
Terminationb 
Visit Safety Follow -up Visit 
28 (¬± 7) Days 
After Last Dose of 
Study Drug  Day 1 
 Day 14 
(¬± 3 days) Day 28 
(¬± 3 days)c Day 29 
(¬± 3 days) 
        
Urinalysis  X   X  X X 
Sweat chloriden X   X    
Pregnancy testo Urine  Urine Serum  Serum Xp 
VX-661 and M1 -661 PKq   X X  X X 
IVA and M1 -IVA PKq   X X  X  X 
Hematology  X   X  X X 
Coagulation  X   X  X X 
Serum chemistry  X   X  X X 
Lipid panelr X   X  X X 
Vitamin levels  X   X  X X 
        
        
    
 
n Sweat collection will occur before the morning dose and no more than 1  hour before the predose PK  sample collection. Sweat chloride assessments will not overlap with the 
collection of other assessments (see the Laboratory Manual for additional information).  
o Pregnancy tests will be performed for all female subjects of childbearing potential. On Day  1, pregnancy test results must be obtained before randomization. On Day  28, 
pregnancy test results must be obtained before the MCC assessment.  
p Serum pregnancy test must be performed at the ETT Visit for subjects who discontinue the study  and at the Safety Follow-up Visit for subjects who complete the study and 
chose not to enroll in the extension study. Urine pregnancy test must be performed for subjects who complete Day 29 and choo se to enroll in the extension study or for 
subjects who discontinue the study and complete both ETT and Safety Follow -up Visits.  
q Single PK blood samples will be collected within 60  minutes before the morning dose of study drug at Day  28 and Day  29. If study drug is not administered at the visit (i.e., 
study drug interruption or permanent discontinuation of study drug), a PK blood sample will still be collected. At the ETT (as applicable) and the Sa fety Follow -up Visit, a 
single PK blood sample will also be collected.  
r Blood samples for lipid panel tests will be collected after fasting for a minimum of 4  hours (see Section 11.7.2).  

Protocol VX14- 661-111, Version 4.0 Page 11 of 69 
Vertex Pharmaceuticals Incorporated   Table 3-2 Study VX14 -661-111: Treatment Period and Safety Follow- Up Visit 
Event/Assessmenta  Treatment Period  Telephone Contact 
5 Days After WMC 
Administration  Early  
Treatment 
Terminationb 
Visit Safety Follow -up Visit 
28 (¬± 7) Days 
After Last Dose of 
Study Drug  Day 1 
 Day 14 
(¬± 3 days) Day 28 
(¬± 3 days)c Day 29 
(¬± 3 days) 
        
        
Wireless motility capsule (WMC)     Xs Confirm passaget   
Mucociliary clearance assessment (MCC)u   X     
Adverse events and concomitant 
medications  Continuous from signing of ICF through Safety Follow -up Visit 
Randomizationv X       
Meal(s) or snack(s) at sitew X  X Xx    
Study drug dosingy X    
Study drug count  X  X X  X Xz 
CF: cystic fibrosis; ECG: electrocardiogram; FSH: follicle -stimulating hormone; hCG: human chorionic gonadotropin; ; MCC: mucociliary 
clearance; PK: pharmacokinetics; WMC: wireless motility capsule   s Subjects will adhere to study restrictions in Table 9-[ADDRESS_1153662] for 8  hours (water is permitted) before administration of a 
snack bar (in place of the morning meal) with the WMC and the morning dose of study drug , and will fast for an additional [ADDRESS_1153663] will occur 5 days after the administration of the WMC to confirm passage of the capsule (unless the subject  confirms passage of the capsule before the 
scheduled telephone contact). If passage of the WMC is not confirmed by [CONTACT_831236], the medical monitor must be contact[CONTACT_831237]. Passage of the WMC must be confirmed by [CONTACT_831231] X -ray, regardless of confirmation of passage by [CONTACT_831235] (see Section 11.4.3 and 
the Study Reference Man ual for additional information).  
u On Day 28, radiolabeled aerosol inhalation will occur after the dose of study drug. One MCC scan will occur immediately following radiolabeled aerosol inhalation and a 
second scan approximately 6  hours (¬± 30 minutes) afte r inhalation. Subjects will adhere to study restrictions in Table 9-1 related to MCC (see the Study Reference Manual for 
additional information). Refer  to Section 8.1.[ADDRESS_1153664] dose of study drug. Randomization may occur on Day  -1. 
w Fat-containing food such as a ‚Äústandard CF‚Äù high-fat, high -calorie meal or snack will be provided at the site to subjects after all predose assessments have occurred (if the 
Day 28 assessments occur on 2 separate days, a meal or snack will be provided for each clinic visit.).  
x Administration of a snack bar (in place of the morning meal).  
y Study drug will be administered as described in Section 10.2. On Day  1 through the morning of  the Day 29 Clinic Visit, study drug will be administered within 30  minutes of 
starting a meal with fat-containing food such as a ‚Äústandard CF‚Äù high-fat, high -calorie meal or snack. At the Day  [ADDRESS_1153665] of Figures  .......................................................................................................................... 16  
5 Introduction.......................................................................................................................... 17 
6 Study Objective .................................................................................................................... 18  
7 Study Endpoints  ................................................................................................................... 18  
7.1 Key Endpoints ................................................................................................................ 18  
  
8 Study Design  ......................................................................................................................... 19  
8.1 Overview of Study Design ............................................................................................. 19  
8.1.1  Screening  ................................................................................................................ 20  
[IP_ADDRESS]  Repetition of Screening Assessment(s)  ............................................................ 21  
[IP_ADDRESS]  Rescreening  ...................................................................................................... 21  
[IP_ADDRESS]  Extension of Screening Period Window .......................................................... 22  
8.1.2  Treatment Period  .................................................................................................... 22  
8.1.3  Safety Follow -up Visit............................................................................................ 23  
8.1.4  Early Treatment Termination  ................................................................................. 23  
8.2 Rationale for Study Design and Study Drug Regimens ................................................. 23  
8.2.1  Study Design ........................................................................................................... 23 
8.2.2  Study Drug Dose and Duration .............................................................................. 23  
8.2.3  Rationale for Study Population............................................................................... 23  
8.2.4  Rationale for Study Assessments  ........................................................................... 24  
9 Study Population  .................................................................................................................. 25  
9.1 Inclusion Criteria  ............................................................................................................ 25  
9.2 Exclusion Criteria  ........................................................................................................... 26  
9.3 Study Restrictions  ........................................................................................................... 29  
9.3.1  Additional Dietary Restrictions/Prohibited Medications  ....................................... [ADDRESS_1153666] of Tables  
Table 3-1  Study VX14 -661-111: Screening Period  ................................................................ 6  
Table 3-2  Study VX14 -661-111: Treatment Period and Safety Follow- Up Visit .................. [ADDRESS_1153667] Panels  .............................................................................. 42  
Table 12-1 Power for Within -Group Comparison (100 mg VX-661 qd + 150 mg IVA q12h) 
for ppFEV 1 With N = 36 and ‚àÜ = 4.5% ................................................................ 50  
Table 12-2 Power for Within -Group Comparison (100 mg VX-661 qd + 150 mg IVA q12h) 
for Average % Whole Lung Clearance Through 60 Minutes With N = 36 and 
‚àÜ = 6% .................................................................................................................. 50  
Table 12-3 Power for Within -Group Comparison (100 mg VX-661 qd + 150 mg IVA q12h) 
for Small Bowel AUC Over 1 -minute Mean pH In crements Through 30 Minutes 
After Gastric Emptying With N  = 36 and ‚àÜ = 22 pH Minutes (or Equivalently, 
0.73 pH) ................................................................................................................ 50  
Table 12-4 Power for Within -Group Comparison (100 mg VX-661 qd + 150 mg IVA q12h) 
for Sweat Chloride With N = 36 and ‚àÜ = -5 mmol/L  ........................................... [ADDRESS_1153668] of Figures  
Figure 8-1 Schematic of the Study Design  ............................................................................. 20  

Protocol VX14- 661-111, Version  4.0 Page 17 of 69 
Vertex Pharmaceuticals Incorporated   5 INTRODUCTION 
Cystic fibrosis (CF) is an orphan disease1,[ADDRESS_1153669] morbidity and mortality 
are caused by [CONTACT_831238], the disease affects multiple organs.6 
CF is an autosomal recessive genetic disease caused by [CONTACT_831239] (CFTR), an epi[INVESTIGATOR_831209]-dependent protein kinase A that is responsible for aiding in the regulation of salt and water absorption and secretion in various tissues.
4 This function is 
defective in patients with CF due to a loss of either cell surface expression and/or function. 
The most prevalent mutation is an in -frame deletion in the CFTR gene resulting in a loss of 
phenylalanine at position 508 in the CFTR protein (F508del-CFTR). The proportion of patients 
with CF who are homozygous for the F508del- CFTR mutation is similar across geographic 
regions: approximately 47% in the US,7 44% in the European Union (EU),8 49% in Canada,9 and 
52% in Australia.[ADDRESS_1153670] been studied.
17 One approach is to treat with a compound (CFTR ‚Äúcorrectors‚Äù) 
that will modify the cellular processing and trafficking of the CFTR protein to increase the amount of functional CFTR at the cell surface. Another approach is to treat with compounds (‚Äúpotentiators‚Äù) that increase the channel gating activity of protein kinase A- activated CFTR at 
the cell surface to enhance ion transport. Depending on the amount of residual CFTR channel activity in the membrane and the pathophysiology of that activity (reflecting the CFTR genotype of the patient and possibly other factors), both approaches may be required to ameliorate lung disease in patients with CF. A modest restoration of chloride secretion through the action of a 

Protocol VX14- 661-111, Version  4.0 Page 18 of 69 
Vertex Pharmaceuticals Incorporated   potentiator and/or corrector could prevent the hyperabsorption of water across the api[INVESTIGATOR_831210], allowing proper maintenance of airway hydration. Restoration of adequate airway hydration could alleviate the cycle of mucus plugging, infection, and inflammation, 
which leads to irreversible structural changes in the lungs and, eventually, respi[INVESTIGATOR_315404].  
VX-661 is a compound developed by [CONTACT_831240] (Vertex) that has 
been shown to have CFTR corrector properties. Several lines of in vitro evidence suggest that VX-661 works by [CONTACT_139370] a fraction of F508del-CFTR protein during its biogenesis and processing in the endoplasmic reticulum, allowing it to exit the endoplasmic reticulum and traffic to the cell surface.
18 When added for 
more than 24 hours to human bronchial epi[INVESTIGATOR_018] (HBE) cells isolated and cultured from lung explants obtained from donors with CF (CF-HBE cells) who are homozygous for the F508del-CFTR mutation, a concentration- dependent increase in levels of mature (i.e.,  plasma 
membrane) F508del -CFTR was observed. The increased trafficking of F508del- CFTR to the cell 
surface resulted in a substantial increase in Cl
‚àí secretion.[ADDRESS_1153671] the 
processing and localization of other misfolded or normally folded proteins other than CFTR, suggesting that the mechanism of VX -661 action is selective for CFTR (CFTR corrector).
19 
Ivacaftor (IVA, VX -770; Kalydeco [150-mg tablets]) is a compound developed by [CONTACT_831241]. Proof of concept that pharmacologic 
modulation of CFTR function can result in clinical benefit in patients with CF was observed in subjects with CF and the G551D-CFTR mutation who had robust clinical improvement following 
administration of IVA .
20 Kalydeco is currently indicated for treatment of CF in a subset of 
patients with Class  III or ‚Äúgating‚Äù CFTR mutations, including the G551D- CFTR mutation.  
Details about the VX -661 and IVA development programs can be found in the Investigator's 
Brochures.21,22 
6 STUDY OBJECTIVE  
To evaluate the clinical mechanisms of action in lung function and extrapulmonary systems of VX-661 in combination with IVA (VX-661/IVA) in subjects with CF who are homozygous for the F508del-CFTR mutation  
7 STUDY ENDPOINTS  
7.1 Key Endpoints  
‚Ä¢ Absolute change in percent predicted forced expi[INVESTIGATOR_3741] 1 second (ppFEV
1) 
from baseline at Day 28  
‚Ä¢ Absolute change in mucociliary clearance (MCC) from baseline at Day  28 
‚Ä¢ Absolute change in gastrointestinal pH from baseline at Day 29 
‚Ä¢ Absolute change in sweat chloride from baseline at Day  29 
 

Protocol VX14- 661-111, Version  4.0 Page 19 of 69 
Vertex Pharmaceuticals Incorporated   7.2 Other Endpoints  
  
  
‚Ä¢ Safety and tolerability assessments based on adverse events (AEs), clinical laboratory 
values (i.e., serum chemistry, vitamin levels, lipid panel, hematology, coagulation 
studies, and urinalysis), standard 12-lead electrocardiograms (ECGs), vital signs, and pulse oximetry  
8 STUDY DESIGN 
8.1 Overview of Study Desig n 
This is a Phase 2, randomized, double-blind, placebo- controlled, parallel -group, multicenter, 
exploratory study in subjects with CF who are homozygous for the F508del- CFTR mutation. 
This study is designed to evaluate the lung function and extrapulmonary responses of subjects receiving VX -661/IVA combination therapy. 
This study includes a Screening Period, Treatment Period, and a Safety Follow-up Visit. The study plans to randomize approximately 35 subjects and up to approximately 45 subjects. Subjects will be randomized (4:1) to VX-661/IVA or placebo, respectively, as shown in Figure 8-1.  
Subjects who prematurely discontinue study drug treatment will be asked to complete 
assessments as described in Section 8.1.4. 
Subjects who complete the Treatment Period and are eligible and elect to roll into an extension study will be required to have a Safety Follow- up visit 28 ¬± [ADDRESS_1153672] dose of study 
drug. 

3URWRFRO9;9HUVLRQ 3DJHRI
9HUWH[3KDUPDFHXWLFDOV,QFRUSRUDWHG )LJXUH 6FKHPDWLFRIW KH6WXG\'HVLJQ
0&&PXFRFLOLDU\FOHDUDQFHSS)(9SHUFHQWSUHGLFWHGIRUFHGH[ SLUDWRU\YROXPHLQVHFRQG6Z&OVZHDW
FKORULGH:0&ZLUHOHVVPRWLOLW\FDSVXOH
1RWH2QO\NH\DVVHV VPHQWVDUHLQFOXGHGLQWKHILJXUH
D6WXG\GUXJZLOOEHDGPLQLVWHUHGIRUGD\¬ìGD\VDQGWKHO DVWGRVHRIVWXG\GUXJZLOOEHDGPLQLVWHUHGDWWKH
'D\9LVLW
E7KH6DIHW\)ROORZXS9LVLWLVVFKHGXOHGWRRFFXU¬ìGD\V DIWHUWKHODVWGRVHRIVWX G\GUXJIRUDOOVXEMHFWV
F6XEMHFWVZKRFRPSOHWHWKH'D\ 9LVLWDQGVXEVHTXHQWO\WKH6DI HW\)ROORZXS9LVLWZLOOEHRIIHUHGWKH
RSSRUWXQLW\WRHQUROOLQDQH[WHQVLRQVWXG\RI9;,9$FRPEL QDWLRQWKHUDS\LIWKH\PHHWHOLJLELOLW\
UHTXLUHPHQWVIRUWKHH[WHQVLRQVWXG\
 6FUHHQLQJ
6FUHHQLQJDVVHVVPHQWVDUHVKRZQLQ 7DEOH$OOYLVLWVVKRXOGRFFXUZLWKLQWKHZLQGRZV
VSHFLILHG6XEMHFWVZLOOEHRXWSDWLH QWVGXULQJWKH6FUHHQLQJ3H ULRG
7KH6FUHHQLQJ3HULRGZLOORFFX UEHWZHHQDQGGD\VEHIRUHWK HILUVWGRVHRIVWXG\GUXJWR
FRQILUPWKDWWKHVXEMHFWVPHHWWKHHOLJLELOLW\FULWHULD7KHLQ YHVWLJDWRURUD QDSSURSULDWH
DXWKRUL]HGGHVLJQHHZLOOREWDLQL QIRUPHGFRQVHQWIURPHDFKVXE MHFWEHIRUHEHJLQQLQJDQ\VWXG\
DVVHVVPHQWV7RSUHSDUHIRUVWXG \SDUWLFLSDWLRQVXEMHFWVZLOO EHLQVWUXFWHGRQWKHVWXG\
UHVWULFWLRQV 6HFWLRQ 
'XULQJWKH6FUHHQLQJ3HULRGDSD WHQF\FDSVXOHDQGDZLUHOHVVP RWLOLW\FDSVXOH:0&ZLOOEH
DGPLQLVWHUHG7KHSDWHQF\FDSVXOH ZLOOEHDGPLQLV WHUHGDWWKH' D\WR'D\&OLQLF9LVLW$
WHOHSKRQHFRQWDFW ZLOORFFXUGD\VDIWHUDGPLQLVWUDWLRQRIWKH SDWHQF\FDSVXOHWRFRQILUPWKH
SDVVDJHRIWKHFDSVXOHLQWKHVW RROXQOHVVWKHVXEMHFWFRQILUP VSDVVDJHRIWKHFDS VXOHSULRUWRWKH
VFKHGXOHGWHOHSKRQHFRQWDFW,I SDVVDJHRIWKHSDWHQF\FDSVXOH LVQRWFRQILUPHGE\WKHWHOHSKRQH
FRQWDFWWKHPHGLFDOPRQLWRUPXVWEHFRQWDFWHGLPPHGLDWHO\WRF RQILUPIXUWKHUFRXUVHRIDFWLRQ
6XEMHFWVZKRDUHXQDEOHWRVXFFH VVIXOO\SDVVWKHSDWHQF\FDSVXO HWHVWZLOOQRWEHUDQGRPL]HGVHH
WKH6WXG\5HIHUHQFH0DQXDOI RUDGGLWLRQDOLQIRUPDWLRQ
$WHOHSKRQHFRQWDFWZLOORFFXUGD \VDIWHUDGPLQLVWUDWLRQRIW KH:0&WRFRQILUPWKHSDVVDJHRI
WKHFDSVXOHXQOHVVWKHVXEMHFW FRQILUPVSDVVDJHRIWKHFDSVXOH SULRUWRWKHVFKHGXOHGWHOHSKRQH
FRQWDFW,ISDVVDJHRIWKH:0& LVQRWFRQILUPHGE\WKHWHOHSKR QHFRQWDFWWKHPHGLFDOPRQLWRU
PXVWEHFRQWDFWHGLPPHGLDWHO\WRF RQILUPIXUWKHUFRXUVHRIDFWL RQ)LQDOFRQILUPDWLRQRISDVVDJH
ZLOOEHREWDLQHGE\WKHFHQWUDOUH DGHUIROORZLQJUHYLHZRIWKH GDWD,IWKH:0& GDWDUHYLHZLV

Protocol VX14- 661-111, Version  4.[ADDRESS_1153673] (see the 
Study Reference Manu al for additional information).  
To allow flexibility, the Clinic Visit Day  -23 to Day -10 may occur on 1 day or on 2 separate 
days as follows (see Table 3-1):   
‚Ä¢ Spi[INVESTIGATOR_831211].  
‚Ä¢ If WMC administration and MCC occur on a single day, spi[INVESTIGATOR_831212], and WMC administration should occur before MCC.  
‚Ä¢ A urine pregnancy test will be completed  before WMC administration and the MCC; if 
WMC administration and MCC occur on 2 separate days, pregnancy testing will occur 
before the procedures on each day .  
‚Ä¢ If assessments occur on 2 separate days, a meal or snack bar will be provided at the clinic 
on both days. 
‚Ä¢ Fasting will occur only on the day of WMC administration. 
Subjects will be outpatients during the Screening Period. 
[IP_ADDRESS] Repetition of Screening Assessment(s)  
Repetition of individual screening assessment(s) that did not meet eligibility criteria is not 
permitted with the following exceptions: 
‚Ä¢ If there is clear evidence of a laboratory error (e.g.,  hemolyzed sample) or equipment 
malfunction, collec tion of a repeat sample for the appropriate laboratory test or assessment 
may be permitted with the approval of the medical monitor.  
‚Ä¢ Exclusionary liver function test (LFT) levels, which may be retested within 14 days of the 
original screening date.  
‚Ä¢ If screening spi[INVESTIGATOR_489359]/European Respi[INVESTIGATOR_139600],23 repeat 
spi[INVESTIGATOR_94230], after discussion with the medical monitor. 
If repeat values of the individual assessment(s) described above are within the eligibility criteria 
and completed within the screening window, then the subject will be eligible for the study, provided they meet all eligibility criteria.  
[IP_ADDRESS] Rescreening  
Subjects may only be rescreened with the approval of the medical monitor. If a subject is rescreened, all Screening Visit (Day  -28 to Day - 13) assessments will be repeated except for the 
following: 
‚Ä¢ Patency capsule assessment  
‚Ä¢ Ophthalmology examination (if performed within the last 3 months) 
‚Ä¢ CF genotypi[INVESTIGATOR_831213]14- 661-111, Version  4.0 Page 23 of 69 
Vertex Pharmaceuticals Incorporated   8.1.3 Safety Follow- up Visit 
The Safety Follow -up Visit assessments are listed in Table 3-2. The Safety F ollow-up Visit will 
occur approximately 28  (¬± 7) days after the last dose of study drug for all subjects, including 
subjects who discontinue treatment (see Section 8.1.4).  
Subjects who complete the Day 29 Visit and subsequently the Safety Follow- up Visit will be 
offered the opportunity to enroll into an extension study of VX-661/IVA combination therapy if 
they meet eligibility requirements for the extension study.  
8.1.[ADDRESS_1153674] prematurely discontinues study treatment, an Early Treatment Termination Visit (ETT) should be scheduled as soon as possible after the last dose of study drug. Subjects who prematurely discontinue treatment will also be required to complete the Safety Follow -up Visit, 
approximately 28 (¬± 7) days after their last dose of study drug. The assessments performed at the 
ETT and Safety Follow- up Visit are listed in  Table 3-2. 
If the ETT Visit occurs [ADDRESS_1153675]. 
This study is designed to observe the effects of VX -661 (100 mg  daily [qd]) and IVA 
(150 mg every 12 hours [q12h]) combination therapy on lung function (measured by [CONTACT_66763]
1 and 
MCC), gastrointestinal pH, and CFTR modulation (sweat chloride). These data will be 
informative for understanding the underlying clinical mechanisms of physiological 
improvements derived from CFTR modulation. 
8.2.2 Study Drug Dose and Duration 
The dose regimen of VX-661 for this study is equivalent to the dose evaluating VX-661/IVA 
combination ther apy in a Phase 2 study, Study VX11-661-101 (Study 101), and is the same dose 
selected for the Phase 3 studies.21 The dose regimen of 100- mg VX-661 qd/ 150 mg  IVA q12h 
provided clinically meaningful and statistically significant improvements in ppFEV 1 in 
Study 101 with 28 days of treatment in subjects ho mozygous for the F508del -CFTR mutation. In 
addition, a trend of decreased sweat chloride levels was observed with VX-661/IVA combination therapy at multiple dose levels investigated in Study 101 in subjects heterozygous and homozygous for the F508del- CFTR mutation.
21Finally, in a separate study evaluating IVA 
monotherapy in patients with the G551D-CFTR mutation, improvements were observed within 1 month in both ppFEV1 and MCC, as well as in gastrointestinal pH as measured by [CONTACT_831242].
24 
Based on the timing of these treatment effects in those studies , a 4-week placebo -controlled 
duration was considered adequate. 
8.2.3 Rationale for Study Population 
The study population will be subjects with CF who are 18 years of age and older and are 
homozygous for the F508del- CFTR mutation. The F508del- CFTR mutation interferes with the 
processing and trafficking of the CFTR protein, resulting in decreased chloride transport.18,19 In 

Protocol VX14- 661-111, Version  4.0 Page 24 of 69 
Vertex Pharmaceuticals Incorporated   Study 101, subjects homozygous for F508del- CFTR who were treated with VX -661/IVA 
combination therapy had statistically significant and clinically meaningful improvements in 
ppFEV 1, supporting the further development of VX-661/IVA combination therapy.21 The 
baseline characteristics of the population to be enrolled in this study are anticipated to be similar to the subset of subjects aged 18 years and older in the Phase 3 study (Study VX14-661-106) of 
VX-661/IVA combination therapy in subjects homozygous for F508del- CFTR. 
8.2.4 Rationale for Study Assessments 
The rationale for all efficacy assessments, including those related to lung function (ppFEV1), MCC, gastrointestinal pH, and sweat chloride, is provided below. Given the complexity and duration required to complete these assessments, clinical visits have been extended over multiple days within the screening and treatment periods. The safety assessments are standard parameters for clinical studies in d rug development. The pharmacokinetics (PK) assessment ( Section 11.3) is 
included to assess exposure to study drug. 
Spi[INVESTIGATOR_831214] -661/IVA combination therapy on lung function, ppFEV 1 will be 
assessed as a measure of air flow in the lungs. Since lung disease is the major cause of morbidity and mortality for patients with CF, CF lung disease is the desired primary target of VX -661/IVA 
combination therapy. Spi[INVESTIGATOR_831215]. 
MCC 
Mucus clearance is an innate airway defense mechanism for clearing bacteria and viruses, which is dependent on adequate airway surface hydration. It is hypothesized that patients with CF have defects in airway hydration, which in turn slows mucus clearance and promotes airway obstruction and subsequent infection. In a study evaluating IVA monotherapy in patients with the 
G551D-CFTR mutation, improvements were observed in both ppFEV
[ADDRESS_1153676] of VX -661/IVA combination therapy on 
MCC will also be assessed in this study using an imaging technique that enables the tracking of mucus within the airways.  
Gastrointestinal pH  
In addition to studying effects in the pulmonary system, and given that CFTR transports bicarbonate and chlori de, the effect of VX -661/IVA combination therapy on gastrointestinal pH 
will be assessed. Efficient neutralization of gastric acid in the proximal portion of the small intestine is an important factor in optimal nutrient absorption and digestion. Patients with CF have reduced bicarbonate secretion from the pancreas and gastrointestinal mucosa,
25, 26,27 and a 
more acidic small intestinal milieu as compared with healthy controls,28 resulting in increased 
mucus viscosity, inefficient pancreatic enzyme activity and  malnutrition. In a study evaluating 
IVA monotherapy in patients with the G551D-CFTR mutation, IVA treatment results in 
improvement in the pH of the small bowel, as measured using an ingested capsule device (a WMC).
[ADDRESS_1153677] of VX -661/IVA combination therapy on bicarbonate secretion 
will also be assessed in this study using gastrointestinal pH as determined by a WMC.  
 

Protocol VX14- 661-111, Version  4.0 Page 26 of 69 
Vertex Pharmaceuticals Incorporated   received before randomization, a previous CFTR genotype laboratory report may be used to 
establish eligibility. Note: Subjects who have been randomized and whose screening 
genotype results do not confirm study eligibility must be discontinued from the study as 
described in Section 9.5.  
4. Confirmed diagnosis of CF32 defined as a sweat chloride value ‚â•60 mmol/L by [CONTACT_831243][INVESTIGATOR_315411] (as documented in the subject's medical record OR from sweat chloride test r esult obtained during screening, if subject does not have a sweat chloride test 
result in the medical record).  
5. FEV
1 ‚â•40% and ‚â§90% of predicted normal for age, sex, and height (equation of Hankinson 
et al.)33 during the Day -28 to Day -13 Screening Visit ( Section 11.4.1). Spi[INVESTIGATOR_577206]/European Respi[INVESTIGATOR_14445]23 
for acceptability and repeatability ( Section [IP_ADDRESS]). 
6. Stable CF disease as judged  by [CONTACT_093].  
7. Willing to remain on a stable CF medication regimen as described in Section 9.[ADDRESS_1153678] not passed the patency capsule 
and WMC.  
9.2 Exclusion Criteria  
Subjects who meet any of the following exclusion cr iteria will not be eligible for this study: 
1. History of any comorbidity that, in the opi[INVESTIGATOR_871], might confound the results 
of the study or pose an additional risk in administering study drug to the subject. For example: 
‚Ä¢ History of cirrhosis with portal hypertension, and/or history of risk factors for Torsade de 
Pointes (e.g., familial long QT syndrome, hypokalemia, heart failure, left ventricular 
hypertrophy, bradycardia, myocardial infarction, cardiomyopathy, history of arrhythmia 
[ventricular and atrial fibrillation], obesity, acute neurologic events [subarachnoid hemorrhage, intracranial hemorrhage, cerebrovascular accident, and intracranial trauma], and autonomic neuropathy) 
2. Any of the following abnormal laboratory values at scre ening: 
‚Ä¢ Hemoglobin <10 g/dL 
‚Ä¢ Abnormal liver function defined as any 2 or more of the following: ‚â•3 √ó upper limit of 
normal (ULN) aspartate aminotransferase (AST), ‚â•3  √ó ULN alanine aminotransferase 
(ALT), ‚â•3  √ó ULN gamma -glutamyl transpeptidase (GGT), ‚â•3 √ó ULN  alkaline 
phosphatase (ALP), or ‚â•2 √ó ULN total bilirubin  
‚Ä¢ Abnormal liver function defined as any increase of ‚â•5 √ó ULN AST or ALT  
‚Ä¢ Abnormal renal function defined as glomerular filtration rate ‚â§50 mL/min/1.73 m
2 
(calculated by [CONTACT_139377])34,35 

Protocol VX14- 661-111, Version  4.0 Page 27 of 69 
Vertex Pharmaceuticals Incorporated   3. An acute upper or lower respi[INVESTIGATOR_4416], pulmonary exacerbation, or changes in therapy 
(including antibiotics) for pulmonary disease within 28 days before Day 1 (first dose of study drug) 
4. A standard 12- lead ECG demonstrating QTc >[ADDRESS_1153679]'s eligibility  
5. History or evidenc e of cataract, lens opacity, Y -suture, or lamellar rings determined to be 
clinically significant by [CONTACT_831244]. The ophthalmologic examination does not need to be repeated if there 
is documentation of an examination meeting protocol criteria that was conducted within 3 months before the Screening Period ( Section 11.7.7).  
6. History of solid organ or hematological transplantation 
7. History of alcohol or drug abuse, as deemed by [CONTACT_093], in the past year, including but not limited to  cannabis, cocaine, and opi[INVESTIGATOR_858] 
8. Ongoing or prior participation in an investigational drug study as follows: 
‚Ä¢ A washout period of 5 terminal half -lives of the previous investigational study drug (i.e., 
non-CFTR modulators) or  [ADDRESS_1153680] elapse before screening. 
The duration of the elapsed time may be longer if required by [CONTACT_427]. 
‚Ä¢ Subjects with previous participation in an investigational study of VX-661, lumacaftor, or 
another CFTR modulator within [ADDRESS_1153681] be confirmed by [CONTACT_7195].  
‚Ä¢ Ongoing participation in any observational (noninterventional) study, including studies 
requiring assessment without administration of study drug, is permitted.  
9. Use of restricted medications or foods within the specified window before the first dose of 
study drug and before specific assessments as defined in Section 9.3. 
10. Pregnant or nursing females (females of childbearing potential must have negative pregnancy test in the Screening Period and at the Day 1 Visit)  
11. Sexually active subjects of reproductive pote ntial who are not willing to follow the 
contraception requirements outlined in Section [IP_ADDRESS] 
12. The subject or a close relative of the subject is t he investigator or a subinvestigator, research 
assistant, pharmacist, study coordinator, or other staff directly involved with the conduct of the study. An adult (aged 18 years or older) who is a relative of a study staff member may be randomized in the study provided that 
‚Ä¢ the adult lives independently of and does not reside with the study staff member 
‚Ä¢ the adult participates in the study at a site other than the site at which the family member 
is employed  

Protocol VX14- 661-111, Version  4.0 Page 28 of 69 
Vertex Pharmaceuticals Incorporated   13. Colonization with organisms associated with a more rapid decline in pulmonary status (e.g., 
Burkholderia cenocepacia, Burkholderia dolosa, and Mycobacterium abscessus ). For 
subjects who have had a history of a positive culture in the past, the investigator could be guided by [CONTACT_139380] a subject to be considered free of colonization: 
‚Ä¢ The subject should have had [ADDRESS_1153682] 12 months, with no subsequent positive cultures. 
‚Ä¢ These [ADDRESS_1153683] 3  months. 
‚Ä¢ One of these [ADDRESS_1153684] MCC procedure that 
would cause them to exceed federal reg ulations by [CONTACT_4907] (whole body 
exposure >5 Rem [50 mSv] for adults) 
15. In the opi[INVESTIGATOR_871], unable to adequately perform inhalation maneuvers needed for isotope deposition during the MCC procedures 
16. Additional exclusion crit eria related to administration of WMCs include:  
‚Ä¢ History of any intraperitoneal abdominal or pelvic surgery (cesarean section, cholecystectomy and appendectomy are permitted if performed >3 months before the patency assessment during screening) or surgery i nvolving the luminal gastrointestinal tract. The 
Vertex medical monitor should be contact[CONTACT_831245]. 
(Note: A percutaneous endoscopic gastrostomy [PEG] tube in the past or present or an 
extraperitoneal abdominal surgery, such as an inguinal he rnia or umbilical hernia repair, are 
not exclusionary.) 
‚Ä¢ Clinical or radiographic evidence of bowel obstruction or stricture within the last 12 months 
‚Ä¢ Prior intestinal resection  
‚Ä¢ Previous history of bezoars (the presence of retained liquid, bile, or small amounts of poorly 
organized food residue is permitted) 
‚Ä¢ Presence or history of extensive intestinal diverticulosis, diverticular stricture, and other intestinal strictures  
‚Ä¢ History of inflammatory bowel disease, with or without strictures  
‚Ä¢ Presence or history o f fibrosing colonopathy 
‚Ä¢ Dysphagia to solid food or pi[INVESTIGATOR_3353] (unable to swallow a 13 mm √ó 26  mm capsule)  
‚Ä¢ Use of cardiac medical devices such as pacemakers and defibrillators (gastric stimulators, bladder stimulators, spi[INVESTIGATOR_717818], medication infusion devices, insulin pumps, and 
continuous glucose monitors are permitted) 

Protocol VX14- 661-111, Version  4.0 Page 29 of 69 
Vertex Pharmaceuticals Incorporated   9.3 Study Restrictions  
Study restrictions related to the biomarker assessments are summarized in Table 9-1. 
Table 9-1 Study Restrictions  
Restricted Medication/Food/Activity a Timing of Restriction  
MCC  
No hypertonic saline, bronchodilator, or dornase alfa usage  12 hours before MCC procedures  
WMC  
Food or drink (water permitted)  
 [ADDRESS_1153685] WMC has passed  
Tobacco 8 hours before WMC administration and for 6 
hours immediately after WMC administration  
Alcohol 24 hours before WMC administration until 
capsule has passed  
Rigorous exercise  From WMC administration until capsule has 
passed 
MRI No MRI from patency capsule or WMC 
administration until capsule has passed  
MCC: mucociliary  clearance; MRI: magnetic resonance imaging; WMC: wireless motility capsule  
a See Section 9.[ADDRESS_1153686] the 
Vertex medical monitor.  
9.3.1 Additional Dietary Restrictions/Prohibited Medications  
Prohibited medications and certain foods are not allowed in this study (Screening Period through 
Safety Follow -up Visit) ( Table 9-2). Known CYP3A4 inducers and inhibitors are restricted 
because VX -[ADDRESS_1153687] of study prohibitions and cautions for food and medication will be provided 
in the Study Reference Manual.  

Protocol VX14- 661-111, Version  4.0 Page 30 of 69 
Vertex Pharmaceuticals Incorporated   Table 9-2 Additional Study Restrictions  
Restricted Medication/Food  Study Period  
Screening Period  Treatment Period Through Safety 
Follow-up Visit 
Certain fruits and fruit juices  
(grapefruit, grapefruit juice, 
Seville oranges, marmalade)  None allowed within [ADDRESS_1153688] dose of the study drug  None allowed through the Safety 
Follow-up Visit 
Moderate and strong CYP3A 
inhibitors (except for ciprofloxacin)  None allowed within [ADDRESS_1153689] dose of the study drug  None allowed through the Safety 
Follow-up Visit 
Commercially available CFTR -
modulators (e.g., Kalydeco, 
lumacaftor)  None allowed during Screening 
Period None allowed through the Safety 
Follow-up Visit 
CYP: cytochrome P450; IVA: ivacaftor.  
Note: The use of restricted medication by [CONTACT_139381] a case- by-case basis 
with the medical monitor.  
9.[ADDRESS_1153690]'s CF 
medications, other medications, and herbal and naturopathic remedies administered from at least [ADDRESS_1153691]'s source documents. For subjects who are screened but are not subsequently randomized into the study, details of prior medication will only be documented in the subjects' source documents.  
‚Ä¢ Subjects must remain on a stable medication (and supplement) regimen for their CF from at 
least [ADDRESS_1153692] 28 days before Day  1. Guidelines for stable medication regimens for CF are as follows: 
o Subjects who are taking daily inhaled tobramycin or other chronically inhaled antibiotics should remain on that regimen throughout the study.  
o Subjects who alternate [ADDRESS_1153693] Day of 1 of the inhaled alternating antibiotics. 
‚Ä¢ Subjects may receive doses of prednisone of up to 10 mg/day (chronically) or prednisone 
60 mg qd for up to 5 days without prior approval of the medical monitor. 
‚Ä¢ Information about bronchodilator use during the study will be collected and documented. Subjects who are using a bronchodilator must have their spi[INVESTIGATOR_831216] 11.4.1. and Section 11.4.2. 
‚Ä¢ Concomitant use of medications known to prolong the QT interval should be used with 
caution during the study, as the effec t of VX-661/IVA combination therapy on the QT 
interval has not been evaluated in a thorough QT study. Consideration should be given to 

Protocol VX14- 661-111, Version  4.[ADDRESS_1153694] has not withdrawn consent. Subjects will be continued to be followed for safety for 28  days ¬± [ADDRESS_1153695] dose of study drug (see Table 3-2 ). 
If a subject does not return for a scheduled visit, reasonable effort will be made to contact [CONTACT_423]. In any circumstance, reasonable effort will be made to document subject outcome. The investigator will inquire about the reason for withdrawal, request that the subject return all unused investigational product(s), request that the subject return for a Safety Follow-up Vi sit, if 
applicable ( Section 8.1.4), and follow up with the subject regarding any unresolved AEs. 
If the subject withdraws consent, no further evaluations will be performed and no additional data will be collected. Vertex may retain and continue to use any data collected before such withdrawal of consent. 
The investigator should inquire about the reason for withdrawal of consent. Subjects must return all unused study drug. 
A subject will be withdrawn from study drug treatment for any of the following reasons: 
‚Ä¢ A female subject or a female partner of a male subject has a confirmed pregnancy.  
‚Ä¢ A subject‚Äôs treatment is unblinded by [CONTACT_093]. 
A subject may be withdrawn from study drug treatment after a discussion between the 
investigator and the medical monitor for any of the following reasons: 
‚Ä¢ A subject develops a medical condition that requires prolonged concomitant therapy with a 
prohibited medication or prolonged interruption of the study drug. 
‚Ä¢ A subject develops a life- threatening AE or a serious AE (SAE) that places him/her at 
immediate risk, and discontinuation of study drug treatment and withdrawal from the study 
are deemed necessary.  
‚Ä¢ A subject is noncompliant with study requirements. 
‚Ä¢ A subject has an increase in transaminases (ALT or AST) according to evaluations and 
management described in  Section 11.7.8. 
‚Ä¢ A subject has an increase in QTc according to evaluations and management described in Section [IP_ADDRESS]. 
‚Ä¢ A subject develops a cataract or lens opacity.  
Subjects who discontinue study treatment early should complete the assessments of the ETT 
and/or Safety Follow-up Visit, as noted in Section 8.1.4. 

Protocol VX14- 661-111, Version  4.[ADDRESS_1153696] be discontinued from study drug treatment, will undergo ETT and/or Safety 
Follow-up Visits per Section 8.1.3 and Section 8.1.4, and will then be discontinued from the 
study. After discontinuation of study drug treatment, these subjects will not undergo any further assessments other than those performed at the ETT and /or Safety Follow- up Visits.  
9.[ADDRESS_1153697] approximately 35 subjects completing the study. 
10 STUDY DRUG ADMINISTRATION AND MANAGEMENT  
Study drug refers to VX -661/IVA, IVA, and their matching placebos. 
10.1 Preparation and Dispensing  
Study drug may be dispensed only under the supervision of the investigator or an authorized 
designee and only for administration to the study subjects. 
10.2 Administration  
Study drug tablets will be administered orally during the Treatment Period as shown in 
Table 10-1. 
Table 10-1 Study Drug Administration - Treatment Period  
Treatment Arm  Time Drug(s) and Dose(s) Administered  
Route of Administration  
VX-661/IVA 
 AM 100-mg VX-661 / 150 -mg IVA FDC tablet,  
oral 
PM 150-mg IVA tablet,  
oral 
Placebo 
 AM VX-661/IVA-matching placebo FDC tablet,  
oral 
PM IVA-matching placebo tablet,  
oral 
AM: morning; FDC: fixed dose combination; IVA: ivacaftor; PM: evening.  
Study drug should be administered within 30 minutes of starting a meal with fat-containing food 
such as a ‚Äústandard CF‚Äù high -fat, high- calorie meal or snack according to the following 
guidelines: 
1. Throughout the Treatment Period, study drugs will be administered after the start and before 
the end of a meal. It is recommended that the duration of each meal associated with study drug intake (i.e., breakfast and dinner/snack, as applicable) should not exceed 30 minutes.  
2. Study drug should be administered q12h (¬± 2 hours). For each subject, all doses (morning and evening) of study drugs will be taken at approximately the same time each day. For example, the morning dose could be taken at 08:00 every morning and the evening dose could be taken at 20:[ADDRESS_1153698] 's scheduled visit is  to occur in the afternoon, the following guidelines must be 
used: 
‚Ä¢ If the dose in the clinic will be within [ADDRESS_1153699]'s scheduled morning dose, 
the subject should withhold their morning dose of study drug and the morning dose will 
be administered in the clinic.  
‚Ä¢ If the dose in the clinic will be more than [ADDRESS_1153700]'s scheduled morning 
dose, the subject should take the morning dose at home and the evening dose will be administered in the clinic. In this event, all assessments will be collected relative to the evening dose. 
8. For visits after the Day  1 Visit, subjects will be instructed to bring all used and unused study 
drug to the site.  
10.3 Method of Assigning Subjects to Treatment Groups  
A target of approximately 35 subjects, with up to approximately 45, who meet the eligibility criteria 
will be randomized in a ratio of 4:1 (active study drug:placebo).  An interactive web response 
system (IWRS) will be used to assign subjects to treatment. Detailed instructions for 
randomization will be provided separately.  
10.[ADDRESS_1153701] should take 
his/her dose with food. If more than [ADDRESS_1153702] elapsed after his/her usual dosing time, the subject should skip that dose and resume his/her normal schedule for the following dose. For example, 
‚Ä¢ If the morning dose of study drug should have been taken at approximately 08:00, and the 
subject remembers at 12:00 that he/she forgot to take that dose, he/she should take the dose 
with food as soon as possible. 
‚Ä¢ If the morning dose of study drug should have been taken at approximately 08:00, and more than [ADDRESS_1153703] elapsed beyond the scheduled dosing time (i.e., the time is past 14:00), the subject would resume dosing with the evening dose at approximately 20:00. 
10.5 Dose Modification for Toxicity 
The dosage of VX-661 or ivacaftor cannot be altered, but the investigator can stop treatment (Section 9.5). 

Protocol VX14- 661-111, Version  4.0 Page 34 of 69 
Vertex Pharmaceuticals Incorporated   10.6 Packaging and Labeling 
Vertex will supply the 100 -mg VX-661 / 150-mg IVA FDC tablets, VX661/IVA- matching 
placebo FDC tablets, 150-mg IVA tablets, and IVA-matching placebo tablets. Study drug 
labeling will be in compliance with applicable local and national regulations. Additional details regarding packaging, labeling, and dispensing for the study drugs will be included in the Pharmacy Manual.  
10.7 Study Drug Supply, Storage, and Handling  
The investigator, or an authorized designee (e.g., a licensed pharmacist), will ensure that all investigational product is stored in a secured area, under recommended storage conditions, and in accordance with applicable regulatory requirements. To ensure adequate records, all study drugs will be ac counted for as detailed in Section 10.8 or via the drug accountability forms as 
instructed by [CONTACT_139383].  
Table 10-2 Identity of Study Drugs, Dosage, and Storage 
Drug Name  [CONTACT_139419]/Formulation/Route  Dosage Storage Condition  
VX-661/IVA FDC 
tablet 100 mg/150 mg tablet; oral  100 mg/150 mg, 
1 tablet morning dose  ‚â§25¬∞C (77¬∞F) with excursions 
to 30¬∞C (86¬∞F)  
IVA 150 mg tablet, oral  150 mg, 1 tablet 
evening dose  ‚â§25¬∞C (77¬∞F) with excursions 
to 30¬∞C (86¬∞F)  
VX-661/IVA FDC-
matching placebo  0 mg/0 mg tablet; oral  0 mg/0 mg, 1 tablet 
morning dose  ‚â§25¬∞C (77¬∞F) with excursions 
to 30¬∞C (86¬∞F)  
IVA-matching 
placebo 0 mg tablet, oral  0 mg, 1 tablet evening 
dose ‚â§25¬∞C (77¬∞F) with excursions 
to 30¬∞C (86¬∞F)  
FDC: fixed dose combination; IVA: ivacaftor  
10.[ADDRESS_1153704] or designated study site staff will maintain information regarding the dates and amounts of (1) study drug received, (2) study drug dispensed to the subjects, and (3) study drug returned by [CONTACT_748]. Subjects will be instructed to return all used and unused materials associated with the study drug to the site. These materials will be retained at the site according to instructions provided by [CONTACT_139384]. The study monitor will review study drug records and inventory throughout the study. 
10.[ADDRESS_1153705] from the study. 
10.11 Blinding and Unblinding  
This is a double-blind study.  
10.11.1 Blinding  
Blinding of treatment codes and applicable study data will be maintained until the da tabase is 
locked for the final analysis.  
The subjects and all site personnel, including the investigator, the site monitor, and the study 
team, will be blinded with the exception of the following: 
‚Ä¢ Any site personnel for whom this information is important to ensure the safety of the subject 
in the event of a life- threatening medical emergency  
‚Ä¢ Any site personnel for whom this information is important to ensure the safety of the subject 
and her fetus in the event of a pregnancy 
‚Ä¢ Vertex Global Patient Safety (G PS) and Regulatory Affairs personnel to satisfy SAE 
processing and reporting regulations 
‚Ä¢ Unblinded statistician preparing the final (production) randomization list, who is not part of 
the study team  
‚Ä¢ Vertex Clinical Operations IWRS management  
‚Ä¢ Vertex Clinica l Supply Chain 
‚Ä¢ Vendor analyzing PK samples  
‚Ä¢ Vertex medical monitor may, for matters relating to safety concerns, unblind individual 
subjects at any time  
Vertex Drug Metabolism and Pharmacokinetics laboratory personnel will not be involved in the 
conduct of the study and will be unblinded to the bioanalysis results but will remain blinded to subject number and treatment assignment. 
Spi[INVESTIGATOR_139336], knowledge of the spi[INVESTIGATOR_831217] a subject has been administered active study drug or placebo. Therefore, during the conduct of the study, the Vertex study team will have no access to the postdose spi[INVESTIGATOR_831218]. The vendor for central reading of the spi[INVESTIGATOR_139338] (blinded treatment group, with real values for screening and baseline, but with dummy values for all the spi[INVESTIGATOR_831219]) to Vertex to be used for 
developi[INVESTIGATOR_139340]. Furthermore, subjects and their caregiver should not be informed of their study- related spi[INVESTIGATOR_831220].  

Protocol VX14- 661-111, Version  4.[ADDRESS_1153706] access to the sweat chloride data;  
dummy data will be used to develop statistical programs . During the process of locking the 
clinical database, after all study visits have been completed, access to treatment -blinded sweat 
chloride data will be provided to a small group of individuals who are not part of the Vertex study team. This group, which will consist of a biostatistician, a statistical programmer, a validation statistical programmer, and a clinical reviewer, will review the sweat chloride data to ensure there are no significant data issues and will use the blinded data set to refine the statistical programs. 
MCC Blinding 
Despi[INVESTIGATOR_831221], knowledge of the MCC data has the potential to sugg est whether a 
subject has been administered active study drug or placebo. Therefore, during the conduct of the study, the Vertex study team will have no access to the MCC data. Results data will be submitted to a central reader. These individuals, including site staff performing the MCC assessment,  will 
otherwise not be involved in any other aspects of study conduct or subject interaction. 
WMC Blinding 
Despi[INVESTIGATOR_831221], knowledge of the WMC data has the potential to suggest whether a subject has b een administered active study drug or placebo. Therefore, during the conduct of the 
study, the Vertex study team will have no access to the WMC data, except confirmation that the WMC has passed. Results data will be submitted to the central reader, who will otherwise not be involved in any other aspects of study conduct or subject interaction. 
10.11.[ADDRESS_1153707]'s treatment by [CONTACT_155422]'s study treatment is necessary for clinical management. In such cases, investigators will use their best judgment as to whether to unblind without first attempting to contact [CONTACT_14451]. If investigators deem it not necessary to unblind immediately, they will first attempt to contact [CONTACT_14451]. If investigators have tried but are unable to reach the medical monitor, they will use their best judgment, based on the nature and urgency of the clinical situation, and may proceed with unblinding without having successfully reached and discussed the situation with the medical monitor. 
In addition, the Vertex Medical Information Call Center (MICC) will answer 
calls [ADDRESS_1153708]'s treatment assignment has been unblinde d for a medical emergency or urgent clinical 
situation, the medical monitor will be notified within [ADDRESS_1153709] operating procedures 
(SOPs). 
For each visit with a PK blood draw, a record of study drug administration will be collected as described in Section 10.2. The collection date and time that each PK blood sample is drawn will 
also be recorded. 
Details on sample collection, processing, and shippi[INVESTIGATOR_22016] a separate 
protocol-specific Laboratory Manual.  
11.3.[ADDRESS_1153710]: 
‚Ä¢ withheld their short-acting bronchodilators (e.g., albuterol) or anticholinergic (e.g., Atrovent) 
for more than 4 hours before the spi[INVESTIGATOR_1891]; 
‚Ä¢ withheld their long-acting bronchodilator (e.g., salmeterol) for more than 12 hours before the 
spi[INVESTIGATOR_1891]; and  
‚Ä¢ withheld their once-daily, long-acting bronchodilator (e.g., tiotropi[INVESTIGATOR_1893] [Spi[INVESTIGATOR_35444]¬Æ]) 
for more than 24 hours before the spi[INVESTIGATOR_1891]. 
During the Screening Visit, spi[INVESTIGATOR_831222]- or 
postbronchodilators. At all other visits (incl uding the Clinic Visit on Day  -23 to Day -10), all 
spi[INVESTIGATOR_831223]. During the Treatment Period, 
spi[INVESTIGATOR_831224]. 

Protocol VX14- 661-111, Version  4.[ADDRESS_1153711] forgets to withhold bronchodilator(s), spi[INVESTIGATOR_577213]: 
‚Ä¢ If a subject's Clinic Visit Day  -[ADDRESS_1153712] bronchodilator 
spi[INVESTIGATOR_831225], and the visit will not be rescheduled. 
‚Ä¢ If, on Clinic Visit Day  -[ADDRESS_1153713] forgets to withhold his/her dose of 
bronchodilator, then spi[INVESTIGATOR_831226]-bronchodilator, and all 
subsequent spi[INVESTIGATOR_139343] (according to the schedule of assessments detailed in Table 3-2), and the MCC assessment at Day  28, should be performed post-bronchodilator. 
‚Ä¢ Each spi[INVESTIGATOR_831227]. 
If more than [ADDRESS_1153714] scheduled spi[INVESTIGATOR_831228].  
All sites will be provided with spi[INVESTIGATOR_139346]. Spi[INVESTIGATOR_663616] a centralized spi[INVESTIGATOR_139348].  
Subjects should not be informed of their study- related spi[INVESTIGATOR_831229]. 
The following parameters will be determined as part of the spi[INVESTIGATOR_23943] y assessment:  
‚Ä¢ FEV
1 (L) 
‚Ä¢ Forced vital capacity (FVC) (L)  
‚Ä¢ FEV1/FVC (ratio)  
‚Ä¢ Forced expi[INVESTIGATOR_10229] (FEF 25%-75%) (L/s) 
11.4.2 Mucociliary Clearance  
MCC will be assessed as indicated in Table 3-1 and Table 3-2. 
All bronchodilators usage is restricted for 12 hours before the MCC assessments at the Day -23 
to Day -10 Visit and the Day 28 Visit.  
On Day 28, MCC will occur after the dose of study drug. MCC assessments will be performed according to an SOP in the Study Manual. 
Subjects with less than 30 percent predicted FEV
1 on day of MCC, or with acute upper or lower 
respi[INVESTIGATOR_4416], pulmonary exacerbation, or changes in therapy (including antibiotics) for 
pulmonary disease within [ADDRESS_1153715] of MCC testing and submission of results to the central reading center are provided in the Study Reference Manual.  

Protocol VX14- 661-111, Version  4.0 Page 42 of 69 
Vertex Pharmaceuticals Incorporated   documenting, grading, and reporting AEs. A separate document that de tails AE case report form 
(CRF) completion guidelines for investigators as well as training will be provided.  
11.7.[ADDRESS_1153716] results that are abnormal and considered clinically 
significant will be reported as AEs (see Section 13.1). 
The safety laboratory t est panels are shown in Table 11-1. 
Table 11-[ADDRESS_1153717] bilirubin  
Alkaline phosphatase  
Aspartate aminotransferase  
Alanine aminotransferase  
Lactate dehydrogenase  
Gamma-glutamyl transpeptidase  
Total protein  
Albumin 
Creatine kinase 
Amylase 
Lipase 
Vitamin Levels  
Vitamins A, D, E, K, and B12  
Lipid Panel  
Total cholesterol, triglycerides  
Low-density lipoprotein (LDL) 
High-density lipoprotein (HDL)  
 Hemoglobin  
Erythrocytes  
Mean corpuscular hemoglobin  
Mean corpuscular hemoglobin 
concentration  
Mean corpuscular volume  
Reticulocytes  
Platelets 
Leukocytes  
Differential (absolute and percent):  
Eosinophils  
Basophils  
Neutrophils  
Lymphocytes  
Monocytes  
Coagulation Studies  
Activated partial thromboplastin time  
Prothrombin time  
Prothrombin time International Normalized Ratio
 Leukocyte esterase  
Nitrite  
Urobilinogen  
Urine protein  
pH 
Urine blood  
Specific gravity  
Urine ketones  
Urine bilirubin  
Urine glucose  
Note: Day 1, Day 29, ETT, and Safety Follow -up blood draws will be done after a minimum [ADDRESS_1153718]. All other 
blood draws do not require fasting.  
a If urinalysis results are positive for leukocyte esterase, nitrite, protein, or blood, microscopic examination of urine will be performed and results for provided for leukocytes, erythrocytes, crystals, bacteria, and casts.  

Protocol VX14- 661-111, Version  4.0 Page 43 of 69 
Vertex Pharmaceuticals Incorporated   Additional tests at screening: The following additional tests will be performed during screening 
to assess eligibility:  
Clinical laboratory assessments from screening will have no clinically significant findings that 
preclude participation in the study, as judged by [CONTACT_093], for a subject to receive study drug on Day 1. 
Pregnancy (Œ≤ -human chorionic gonadotropin) Tests for Females of Childbearing Potential: 
Serum samples will be obtained as specified in Table 3-1 and Table 3-2 and analyzed at the 
central laboratory. Urine pregnancy tests will be performed at the site as specified in Table 3-1 
and Table 3-2. 
FSH (Screening Period only) : Blood sample for FSH will be measured for any suspected 
postmenopausal female with at least [ADDRESS_1153719] be ‚â•40 mIU/mL to be considered postmenopausal. 
CF Genotype (Screening Period only): CF TR genotypi[INVESTIGATOR_315421]'s medical record (if available). Refer to the Laboratory Manual for details.  
Additional Evaluations: Additional clinical laboratory evaluations will be performed at other 
times if judged to be clinically appropriate.  
For purposes of study conduct, only laboratory tests done in the central laboratory may be used. At the discretion of the local investigator, local laboratories may be used for management of urgent medical issues. If a local laboratory test value is found to be abnormal and clinically significant, it should be verified by [CONTACT_94295]. If it is not possible to send a timely specimen to the central laboratory (e.g.,  the subject was hospi[INVESTIGATOR_94248]), the investigator may base 
the assessment of an AE on the local laboratory value. 
11.7.3 Physical Examinations and Vital Signs 
A physical examination (PE) of all body systems and vital signs assessment will be performed at 
visits noted in Table 3-1 and Table 3-2. At other visits, symptom-directed PEs and symptom-
directed vital sign assessments can be performed at the discretion of the investigator or healthcare provider
. 
A PE includes a review of the following systems: head/neck/thyroid; eyes/ears/nose/throat (EENT); respi[INVESTIGATOR_696]; cardiovascular; lymph nodes; abdomen; skin; musculoskeletal; and neurological. Breast, anorectal, and genital examinations will be performed when medically indicated. After s creening, any clinically significant abnormal findings in PEs will be reported as 
AEs. 
Vital signs include blood pressure (systolic and diastolic), temperature, pulse rate, and respi[INVESTIGATOR_1487]. These will be assessed following a [ADDRESS_1153720] in the supin e position. 
11.7.4 Electrocardiograms  
[IP_ADDRESS] Standard [ADDRESS_1153721] 12-lead ECGs will be performed using a machine with printout according to the Schedule of Assessments ( Table 3-1 and Table 3-2). A window of approximately ¬± [ADDRESS_1153722] 12- lead 

Protocol VX14- 661-111, Version  4.0 Page 44 of 69 
Vertex Pharmaceuticals Incorporated   ECGs will be performed at any other time if clinically indicated. The performance of all ECGs 
will adhere to the following guidelines: 
‚Ä¢ The subject will be instructed to rest in the supi[INVESTIGATOR_21683] 5  minutes before 
having an ECG performed. 
‚Ä¢ The ECG will be performed before any other procedures that may affect heart rate, such as 
blood draws. 
The ECG traces will be manually read at the study site at the Screening and Safety Follow -up 
Visits. A printout of the ECG traces will be made for safety review by [CONTACT_139386]. Clinically significant ECG abnormalities occurring during the study through the Safety Follow-up Visit will be recorded as AEs. 
To ensure safety of the subjects, a qualified individual at the study site will make comparisons to 
baseline measurements. If the QTcF is increased by >45  msec from the baseline or an absolute 
QTcF value is ‚â•500 msec for any scheduled ECG, 2 additional ECGs will be performed approximately 2  to 4 minutes apart to confirm the original measurement. If either of the QTcF 
values from these repeated ECGs remains above the threshold value (>45 msec from baseline or ‚â•500 msec), a single ECG will be repeated at least hourly until QTcF valu es from 2  successive 
ECGs fall below the threshold value that triggered the repeat measurement. 
If the QTc value remains above the threshold value (>45 msec from the average of the 3  predose 
values on Day 1 or >500 msec) on repeated measurement or is noted  on >[ADDRESS_1153723] their QTc monitored closely until it normalizes or returns to baseline.  
11.7.5 Contraception and Pregnancy  
[IP_ADDRESS] Contraception  
The effects of VX -[ADDRESS_1153724] battery of in vitro (Ames test, Chinese hamster ovary cell chromosomal aberration) and in vivo (mouse micronucleus) studies. VX-661 and IVA were each found to be nonteratogenic in reproductive toxicology studies in rats and rabbits.
21,22 Subjects should follow 
the contraception requirements outlined in this study protocol. The effects of VX-661 monotherapy or in combination with IVA on the PK of hormonal contraceptives are not known. Thus, hormonal contraception is not an acceptable method of contraception for female subjects though it is acceptable for the female partners of male subjects.  
At this stage in the development of VX-661/IVA combination therapy, participation in this study requires a commitment from the research subject and his /her partner to use at least  [ADDRESS_1153725] dose of study drug. 
Contraception for the couple is waived for the following:  

Protocol VX14- 661-111, Version  4.0 Page 45 of 69 
Vertex Pharmaceuticals Incorporated   ‚Ä¢ True abstinence for the subject, when this is in line with the preferred and usual lifestyle of 
the subject. Periodic abstinence (e.g.,  calendar, ovulation, symptothermal, postovulation 
methods) and withdrawal are not acceptable methods of contraception. 
‚Ä¢ The male subject is infertile (e.g.,  bilateral orchiectomy). Infertility may be documented 
through examination of a semen specimen or by [CONTACT_139387]. 
‚Ä¢ If the female is of non -childbearing potential, per the following: 
‚Ä¢ Postmenopausal: spontaneous amenorrhea for at least 12 consecutive months and serum FSH level ‚â•40 mIU/mL at screening  
‚Ä¢ Documented hysterectomy or a bilateral oophorectomy/salpi[INVESTIGATOR_8936]-oophorectomy 
‚Ä¢ NOTE: All other female subjects  who have had their first menstrual period will be 
considered to be of childbearing potential. 
Acceptable contraceptive methods:  
Acceptable contraceptive methods for male subjects or male partners of female subjects 
include the following: 
‚Ä¢ Vasectomy 6  months or more previously, with a documented negative postvasectomy 
semen analysis for sperm.  
‚Ä¢ Condom and spermicide. 
‚Ä¢ In countries where spermicide is not available, condom without spermicide will be 
considered acceptable.  
‚Ä¢ Local regulations may require use of an additional acceptable method of contraception.  
Acceptable contraceptive methods for female subjects  include the following: 
‚Ä¢ Bilateral tubal ligation performed at least 6  months previously. 
‚Ä¢ Continuous use of an intrauterine device (non-hormone- releasing) for at least [ADDRESS_1153726] dose of study drug. 
‚Ä¢ Barrier contraception (such as diaphragm, cervical cap, or female condom) and spermicide.  
‚Ä¢ In countries where spermicide is not available, barrier contraception without spermicide will be considered acceptable.  
‚Ä¢ Local regulations may require use of an additional acceptable method of contraception. 
‚Ä¢ NOTE: Hormonal contraceptives will not be considered as an effective method; however, 
female subjects are not required to discontinue hormonal contraceptives. 

Protocol VX14- 661-111, Version  4.0 Page 46 of 69 
Vertex Pharmaceuticals Incorporated   Acceptable contraceptive methods  for female partners of male subjects:  
‚Ä¢ Bilateral tubal ligation performed at least 6  months previously. 
‚Ä¢ Continuous use of an intrauterine device for at least [ADDRESS_1153727] dose of 
study drug.  
‚Ä¢ Barrier contraception (such as diaphragm, cervical cap, or female condom) and 
spermicide.  
‚Ä¢ In countries where spermicide is not available, condom without spermicide will be 
considered acceptable.  
‚Ä¢ Local regulations may require use of an additional acceptable method of contraception. 
‚Ä¢ Hormonal contraceptives, if successfully used for at least [ADDRESS_1153728] dose of study 
drug.  
Additional notes:  
‚Ä¢ Acceptable methods of contraception listed above are examples. Local requirements may 
prohibit the use of some of these examples. Please contact [CONTACT_831246]. 
‚Ä¢ A female condom cannot be used with male condom (as a double method of contraception) due to risk of tearing. 
‚Ä¢ Male and female subjects who are not sexually active at the time of screening must agree to follow the contraceptive requirement s of this study if they become sexually active with a 
partner of the opposite sex. 
‚Ä¢ If applicable, additional contraception requirements may need to be followed according to 
local regulations and/or requirements. 
‚Ä¢ Male subjects must not donate sperm after th e first dose of study drug, throughout the study, 
and for [ADDRESS_1153729] dose of study drug. 
‚Ä¢ Female subjects and female partners of male subjects should not plan to become pregnant 
during the study through [ADDRESS_1153730] dose of study drug. 
‚Ä¢ Male subjects whose female partner becomes pregnant through well-documented in vitro fertilization (donated sperm) or banked sperm (collected before the subject received study 
drug) must be compliant with the contraception requirements. In this sc enario, the male 
subject and his female partner must commit to using barrier methods of contraception (to 
ensure there is no exposure of the fetus to study drug) for the duration of the study and until [ADDRESS_1153731] dose of study drug. 
‚Ä¢ Female subj ects should not nurse a child from the start of study drug dosing through [ADDRESS_1153732] dose of study drug. 
‚Ä¢ Unique situations that may not fall within the above specifications should be discussed with 
the medical monitor.  

Protocol VX14- 661-111, Version  4.0 Page 47 of 69 
Vertex Pharmaceuticals Incorporated   [IP_ADDRESS] Pregnancy  
Subjects will be counseled to inform the investigator of any pregnancy that occurs during study 
treatment and within [ADDRESS_1153733] dose of study drug(s). 
If a female subject or the female partner of a male subject becomes pregnant while participating 
in the study, study drug will be permanently discontinued immediately. For male subjects, study 
drug does not need to be permanently discontinued if the female partner's pregnancy resulted from donated sperm or sperm banked before study drug exposure ( Section [IP_ADDRESS]). The 
investigator must notify the medical monitor and Vertex GPS within 24 hours of the site's knowledge of the subject's (or partner's) pregnancy using the Pregnancy Information Collection Form. 
If the subject is confirmed to be on active drug, the subject or partner will be followed until the end of the pregnancy and the infant will be followed for [ADDRESS_1153734] (seated or supi[INVESTIGATOR_050]) and before study 
drug dosin g. At visits when study drug is taken at the site, pulse oximetry will be collected 
before the morning dose. This is a noninvasive measure of oxygen delivery to the tissues and has been correlated with clinical status and lung function. 
11.7.[ADDRESS_1153735] 
at screening, which includes 
‚Ä¢ measurement of best corrected distance visual acuity of each eye  
‚Ä¢ measurement of lens refracting power following cycloplegia (e. g., autorefractor or 
ophthalmoscopy streak) 
‚Ä¢ pharmacologically dilated examination of the lens with a slit lamp  
The screening ophthalmologic examination must be completed and the results reviewed before randomization. This examination does not have to be repeated if there is documentation of an examination that met protocol criteria and that was within [ADDRESS_1153736] is ineligible for study entry (See Section 9.2). 
Additional ophthalmologic examinations may be conducted at the discretion of the investigator. The medical monitor should be notified of any additional ophthalmologic examinations. 
In addition, at screening, the following history will be obtained for all subjects: 
‚Ä¢ history of steroid use 
‚Ä¢ history or presence of diabetes 

Protocol VX14- 661-111, Version  4.0 Page 48 of 69 
Vertex Pharmaceuticals Incorporated   ‚Ä¢ any prior ophthalmologic or optometric examinations 
‚Ä¢ history of trauma to the eye 
‚Ä¢ any family history of glaucoma, congenital cataracts, or cataracts arising later in life  
‚Ä¢ use of corrective lenses (contact [CONTACT_139390])  
‚Ä¢ history of prolonged exposure to sunlight or ultraviolet light and use of sunglasses 
‚Ä¢ history of exposure to secondhand smoke 
11.7.[ADDRESS_1153737] Parameters  
Liver function testing (ALT, AST, GGT, ALP, and total bilirubin) must be performed as noted in 
Table 3-2. These blood samples should be processed and shipped immediately per the Laboratory Manual.  
Subjects with new treatment -emergent ALT or AST elevations of >3  √ó ULN and clinical 
symptoms must be followed closely, including repeat confirmatory testing performed by [CONTACT_66768] [ADDRESS_1153738] is >5 √ó ULN, follow -up 
levels must be obtained within 7 ¬± [ADDRESS_1153739] the tests repeated and sent to the central laboratory as soon as possible (ideally within 48 to 72 hours). 
Study drug administration must be interrupted immediately (before confirmatory testing), and 
the medical monitor must be notified, if any of the following criteria is met: 
‚Ä¢ ALT or AST >8  √ó ULN 
‚Ä¢ ALT or AST >5  √ó ULN for more than 2 weeks  
‚Ä¢ ALT or AST >3  √ó ULN, in association with total bilirubin >2  √ó ULN a nd/or clinical 
jaundice 
A thorough investigation of potential causes should be conducted and the subject should be followed closely for clinical progression. 
If no convincing alternative etiology (e.g., acetaminophen use, viral hepatitis, or alcohol 
ingestion) for the confirmed elevated transaminases is identified, regardless of whether ALT or 
AST levels have improved, study drug treatment must be permanently discontinued if repeat testing within [ADDRESS_1153740] their transaminases monitored closely until levels normalize or return to baseline. 
Resumption of Study Drug 
If an alternative, reversible cause of transaminase elevation has been identifi ed, study drug may 
be resumed once transaminases return to baseline or are ‚â§2 √ó ULN, whichever is higher. Approval of the medical monitor is required before resumption of study drug. Upon resumption of study drug, transaminases should be assessed weekly while the subject remains on study drug and during the followup. If a protocol- defined transaminase elevation occurs within [ADDRESS_1153741] be permanently discontinued, 
regardless of the presumed etiology. 
12 STATISTICAL AND ANALYTICAL PLANS  
This study is planned as an exploratory study. No type I error control for hypothesis testing will 
be applied, and each of the key endpoints will be assessed individually using a significance level Œ± of 0.05. 
Analysis of a ll data will be performed by [CONTACT_139411](s). Before the database is locked 
for analysis, a detailed plan for the analysis of efficacy and safety data will be presented in a 
statistical analysis plan (SAP), and a detailed plan for PK analysis will be presented in a clinical pharmacology analysis plan (CPAP).  
12.1 Sample Size and Power  
A target of approximately 35  subjects, with up to approximately 45, who meet the eligibility 
criteria will be randomized in a ratio of 4:1 to active study drug or placebo  to maximize power 
across the endpoints. 
The objective of the study is to evaluate the clinical mechanisms of VX -661/IVA combination 
therapy in both lung function and extrapulmonary systems in subjects with CF who are 
homozygous for the F508del  mutation on the CFTR gene. For a subset of the key endpoints 
(specifically, MCC and gastrointestinal pH, as captured in Table 12-2 and Table 12-3), no data 
are available for the F508del homozygous population. Therefore, data for both gastrointestinal 
pH and MCC were compi[INVESTIGATOR_220752] a study evaluating I VA monotherapy in patients with the 
G551D-CFTR mutation  for the purpose of sample size calculation.
24 Mean changes from 
baseline for gastrointestinal pH and MCC endpoints in the combination group were derived assuming approximately 50% of those observed for the active group in the observational study. Standard deviations were assumed to be similar to those observed in the reference studies. For ppFEV
1 and sweat chloride endpoints, sample size assumptions were based on observed data 
from the VX11-661- 101 study.23 
Based on these assumptions, a sample size of 36 subjects in the combination group (based on 45 subjects randomized 4:1) will provide adequate power to detect a statistically significant difference from baseline at Day  28 or 29 for the key endpoints, even after assuming that 10 to 
30% subjects may not have complete data through Day 29 (depending on the endpoint). 
Table 12-[ADDRESS_1153742] an expected mean change from 
baseline (‚àÜ) for key endpoint measures in the VX-661/IVA combination therapy based on a 
sample size of 36  subjects in the VX-661/IVA group using a 2- sided paired t-test at a 
significance level of Œ± = 0.05. More specifically, the endpoint measures include ppFEV
1 at 
Day 28 (Table 12-1), percent whole lung mucus clearance through 60 minutes at Day  28 (Table 
12-2), small bowel area under the curve (AUC) over 1 -minute mean pH increments through 30 
minutes after gastric emptying at Day  29 (Table 12-3), and sweat chloride at Day  29 (Table 
12-4). Further, a sample size of 28 subjects in the VX661/IVA group (resulting in a total of 35 subjects including 7 subjects in the placebo group) will provide at least 80% power to detect the expected mean change from baseline with the expected standard devi ation. Sample size 
calculations were performed using PASS 11 software, Version 11.0.2. Given the exploratory 

Protocol VX14- 661-111, Version  4.0 Page 50 of 69 
Vertex Pharmaceuticals Incorporated   nature of this study, no multiplicity adjustment of type I error will be conducted for the analysis 
of key endpoints. 
 
Table 12-1 Power for Within -Group Comparison ( 100 mg VX -661 qd + 150 mg IVA 
q12h) for ppFEV 1 With N = 36 and ‚àÜ = 4.5%  
Standard deviation  œÉ = 7% (expected)  œÉ = 8% œÉ = 9% œÉ = 10% 
Power 96% 91% 83% 75% 
Power (10% missing data)  95% 88% 80% 71% 
     
N for 80% power  21 27 34 41 
ppFEV1: percent predicted forced expi[INVESTIGATOR_3741] 1 second; IVA: ivacaftor  
 
 
Table 12-2 Power for Within -Group Comparison (100 mg VX-661 qd + 150 mg IVA  
q12h) for Average % Whole Lung Clearance Through 60 Minutes With 
N = 36 and ‚àÜ = 6%  
Standard deviation  œÉ = 6% œÉ = 8% (expected)  œÉ = 10% œÉ = 12% 
Power >99% 99% 94% 83% 
Power (20% missing data)  >99% 97% 88% 74% 
     
N for 80% power  10 16 24 34 
ppFEV1: percent predicted forced expi[INVESTIGATOR_3741] 1 second; IVA: ivacaftor  
 
Table 12-3 Power for Within -Group Comparison (100 mg VX-661 qd + 150 mg IVA 
q12h) for Small Bowel AUC Over 1- minute Mean pH Increments Through 
30 Minutes After Gastric Emptying With N = 36 and ‚àÜ = 22 pH Minutes (or 
Equivalently, 0.73 pH)  
Standard deviation (pH mins)  œÉ = 20 œÉ = 24 (expected)  œÉ = 28 œÉ = 32  
Power >99% >99% >99% 98% 
Power (30% missing data)  >99% >99% 97% 92% 
     
N for 80% power  9 12 15 19 
ppFEV1: percent predicted forced expi[INVESTIGATOR_3741] 1 second; IVA: ivacaftor  
 
Table 12-4 Power for Within -Group Comparison (100 mg VX-661 qd + 150 mg IVA  
q12h) for Sweat Chloride With N = 36 and ‚àÜ = -5 mmol/L  
Standard deviation (mmol/L)  œÉ = 5 œÉ = 6 œÉ = 7 (expected)  œÉ = 8  
Power >99% >99% 99% 95% 
Power (10% missing data)  >99% >99% 98% 94% 
     
N for 80% power  10 14 18 23 
ppFEV1: percent predicted forced expi[INVESTIGATOR_3741] 1 second; IVA: ivacaftor  

Protocol VX14- 661-111, Version  4.[ADDRESS_1153743] data listings and the 
disposition summary table, unless otherwise specified. 
The Full Analysis Set (FAS)  will include all randomized subjects who were F508del  
homozygous and received at least [ADDRESS_1153744] 1  dose of study drug. The Safety 
Set will be used for all safety analyses.  
12.3 Statistical Analysis  
This section presents a summary of the planned statistical analyses of efficacy and safety. Analysis details will be provided in the SAP. 
12.3.1 General Considerations  
Continuous variables will be summarized using the following descriptive summary statistics: the 
number of subjects (n), mean, standard deviation (SD), standard error (SE), median, minimum value (min), and maximum value (max). The precision of the measurement for each continuous variable will be specified in the SAP. Unless otherwise specified, minimum and maximum 
values will be reported with the same precision as the units of the raw data. The mean and median will be reported to [ADDRESS_1153745] units (metric or International System [SI]) will be converted with the appropriate precision. 
Categorical variables will be summarized using counts and percentages. Percentages will be 
presented to [ADDRESS_1153746] recent non- missing 
measurement (scheduled or unscheduled) collected before the first dose of study drug. For ECG, the baseline will be  defined as the average of the most recent triplicate pretreatment 
measurements before the first dose of study drug. 
Change (absolute change) from baseline will be calculated as postbaseline value ‚Äì baseline 
value. 
Relative change from baseline will be calculated as (postbaseline value ‚Äì baseline 
value)/baseline value.  
The treatment -emergent (TE) period will include the time from the first dose to the Safety 
Follow-up Visit or [ADDRESS_1153747] dose of the study drug for subjects who did not complete the Safety Follow -up Visit. 
Rules for handling missing data will be described in the SAP. 

Protocol VX14- 661-111, Version  4.0 Page 52 of 69 
Vertex Pharmaceuticals Incorporated   12.3.2 Background Characteristics  
[IP_ADDRESS] Subject Disposition  
The number and percentage of subjects in each disposition category (e.g., randomized, dosed, 
included in the FAS, included in the Safety Set, completed Treatment Period, completed study/Safety Follow -up Visit, and discontinued treatment or study with a breakdown of the 
reasons for discontinuation for treatment or study, respectively) will be summarized overall a nd 
by [CONTACT_1570]. 
[IP_ADDRESS] Demographics and Baseline Characteristics  
Demographic, background (e.g., medical history), and baseline characteristics will be 
summarized using descriptive summary statistics. Protocol deviations/violations will be provided in an individual subject data listings.  
The following demographics and baseline characteristics will be summarized overall and by [CONTACT_460419] (but are not limited to): sex, race, age, baseline weight, baseline height, baseline body mass index (BMI), baseline ppFEV
1, baseline whole lung 
mucus clearance through 60 minutes, and baseline small bowel AUC over 1-minute mean pH increments through 30 minutes after gastric emptying.  
No statistical tests will be carried out to evaluate any baseline imbalance between treatment 
groups. 
[IP_ADDRESS] Prior and Concomitant Medications  
Medications used in this study will be coded using the World Health Organization Drug 
Dictionary Enhanced and categorized as the following: 
‚Ä¢ Prior medication: any medication that started before initial dosing of study drug, regardless 
of when it ended 
‚Ä¢ Concomitant medication: medication continued or newly received during the TE period 
‚Ä¢ Post-treatment medication: medication continued or newly received after the TE period  
A given medi cation may be classified as a prior medication, a concomitant medication, or a 
post-treatment medication; both prior and concomitant; both concomitant and post- treatment; or 
prior, concomitant, and post- treatment. If a medication has a missing or partially  missing 
start/end date or time and if it cannot be determined whether it was taken before the first dose of 
study drug, concomitantly during the TE period, or after the TE period, it will be considered in all [ADDRESS_1153748] data listing.  
[IP_ADDRESS] Study Drug Exposure and Compliance  
Exposure to study drug will be summarized for the FAS in terms of duration of treatment a subject received (in days), defined as the last day minus the first day  of study drug plus 1. 
Dosing compliance will be summarized for the FAS, and will be derived as 100 √ó  [(total number 
of pi[INVESTIGATOR_91383]) ‚Äì ( total number of pi[INVESTIGATOR_114452])]/( total number of pi[INVESTIGATOR_831230] √ó  duration of study drug exposure in days). 

Protocol VX14- 661-111, Version  4.0 Page 55 of 69 
Vertex Pharmaceuticals Incorporated   ‚Ä¢ All TEAEs  
‚Ä¢ TEAEs by [CONTACT_155429]  
‚Ä¢ TEAEs by [CONTACT_764]  
‚Ä¢ TEAEs leading to treatment discontinuation  
‚Ä¢ Serious TEAEs  
‚Ä¢ TEAEs leading to death  
‚Ä¢ Frequently reported TEAEs  
Summaries will be presented by [CONTACT_489393] (i.e., number and percentage of subjects with an event). When summarizing the number and percentage of subjects with an event, subjects with multiple occurrences of the same AE or a continuing AE will be counted once, only the maximum severity level will be presented in the severity summaries, and the strongest relationship level in the relationship summaries. In addition, a listing containing individual subject level AE data for all deaths and other serious and significant AEs will be provided separately. All AEs, including pre- and post- treatment AEs, will be presented in individual subject data listings.  
[IP_ADDRESS] Clinical Laboratory Assessments 
For the treatment -emergent laboratory measurements, the observed values and change from 
baseline values of the continuous hematology and chemistry results will be summarized in SI units overall and by [CONTACT_139402]. 
The number and percentage of subjects with at least 1 potentially clinically significant (PCS) 
event during the TE period will be summarized overall and by [CONTACT_1570]. The PCS (postbaseline) shift from baseline will also be summarized for selected laboratory parameters. The PCS criteria and the parameter selection criteria will be provided in the SAP.  
Results of urinalysis and the serum pregnancy test will be listed in individual subject data listings only. In addition, a listing containing individual subject hematology, chemistry, and coagulation values outside the reference ranges will be provided. This listing will include data from scheduled and unscheduled time points. 
[IP_ADDRESS] Electrocardiogram  
For the treatment -emergent ECG measurements, a summary of observed values and  change from 
baseline values will be provided overall and by [CONTACT_831247]: RR, PR, QT, and QT corrected for HR intervals (QTcF), QRS duration, and HR. 
The number and percentage of subjects with at least 1 PCS event during the TE period will be 
summarized overall and by [CONTACT_1570]. The PCS (postbaseline) shift from baseline will also be summarized. The PCS criteria will be provided in the SAP. 
Additional ECG analyses will be described in the SAP.  
[IP_ADDRESS] Vital Signs  
For the treatment -emergent vital signs measurements, the observed values and change from 
baseline values will be summarized overall and by [CONTACT_139402]. 

Protocol VX14- 661-111, Version  4.0 Page 56 of 69 
Vertex Pharmaceuticals Incorporated   The following vital signs parameters will be summarized: systolic and diastolic blood pressure 
(mm Hg), body temperature ( ¬∞C), HR (beats per minute), and respi[INVESTIGATOR_697] (breaths  per 
minute). 
The number and percentage of subjects with at least 1 PCS event during the TE period will be 
summarized overall and by [CONTACT_1570]. The PCS (postbaseline) shift from baseline will also 
be summarized. The PCS criteria will be provided in the SAP. 
Additional vital sign analyses will be described in the SAP.  
[IP_ADDRESS] Pulse Oximetry  
For the treatment -emergent pulse oximetry measurements, a summary of observed values and 
change from baseline values will be provided overall and by [CONTACT_831248]. 
The number and percentage of subjects with shift changes from baseline (normal/missing and 
low according to the reference range) to the lowest percent of oxygen saturation during the TE period will be summarized overall and by [CONTACT_1570]. 
[IP_ADDRESS] Physical Examination 
PE findings will be presented in an individual subject data listing only.  
[IP_ADDRESS] Other Safety Analysis 
Not applicable.  
12.4.4 Interim and IDMC Analyses  
Not applicable.  
12.5 Clinical Pharmacology Analysis 
12.5.1 Pharmacokinetic Analysis 
A detailed description of the clinical pharmacology analyses will be provided in a CPAP. 
Listings of plasma concentration data of VX -661, IVA, and their metabolites ( M1-661 and 
M1-IVA) will be provided in the clinical study report. A population approach ma y be used to 
analyze the time-versus- plasma concentration data of VX -661, IVA, and their metabolites. The 
PK/PD relationship between concentrations of VX-661 and IVA and (their metabolites as 
appropriate) and efficacy and safety measurements may be investigated. The results of the PK 
and PK/PD analyses using a population approach will be presented in a separate report. 
13 PROCEDURAL, ETHICAL,  REGULATORY, AND ADMINISTRATIVE 
CONSIDERATIONS  
13.1 Adverse Event and Serious Adverse Event Documentation, Severity Grading, 
and Reporting  
13.1.1 Adverse Events  
[IP_ADDRESS] Definition of an Adverse Event  
An AE is defined as any untoward medical occurrence in a subject during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly 

Protocol VX14- 661-111, Version  4.0 Page 57 of 69 
Vertex Pharmaceuticals Incorporated   occurring event or worsening of a pre-existing condition (e.g., increase in its severity or 
frequency) after the ICF is signed.  
An AE is considered serious if it meets the definition in Section [IP_ADDRESS].  
[IP_ADDRESS] Clinically Significant Assessments  
Study assessments including laboratory tests, ECGs, PEs, and vital signs, will be assessed and 
those deemed a clinically significant worsening from baseline documented as an AE. When 
possible, a clinical diagnosis for the study assessment will be provided, rather than the abnormal test result alone (e.g., urinary tract infection, anemia). In the absence of a diagnosis, the abnormal study assessment itself will be listed as the  AE (e.g., bacteria in urine or decreased 
hemoglobin). 
An abnormal study assessment is considered clinically significant if the subject has 1  or more of 
the following: 
‚Ä¢ Concomitant signs or symptoms related to the abnormal study assessment 
‚Ä¢ Further diagnosti c testing or medical/surgical intervention  
‚Ä¢ A change in the dose of study drug or discontinuation from the study 
Repeat testing to determine whether the result is abnormal, in the absence of any of the above 
criteria, does not necessarily meet clinically significant criteria. The determination of whether the study assessment results are clinically significant will be made by [CONTACT_093].  
A laboratory value that is Grade [ADDRESS_1153749] indicates a life -threatening AE.  
[IP_ADDRESS] Documentation of Adverse Events  
 All AEs will be collected from the time the ICF is signed until the following time points: 
‚Ä¢ For subjects who do not enroll: until time of screen failure (e.g., screen failure, withdrawal of 
consent) 
‚Ä¢ For enrolled subjects: through the Safety Follow- up Visit 
All subjects will be queried, using non-leading questions, about the occurrence of AEs at each 
study visit. When possible, a constellation of signs and/or sym ptoms will be identified as 
1 overall event or diagnosis. All AEs for enrolled subjects will be recorded in the electronic CRF (eCRF) and source document. AEs for subjects who are screened but not subsequently enrolled in the study will be recorded only in the subject's source documents. The following data will be documented for each AE: 
‚Ä¢ Description of the event 
‚Ä¢ Classification of ‚Äúserious‚Äù or ‚Äúnon-serious‚Äù 
‚Ä¢ Date of first occurrence and date of resolution (if applicable) 
‚Ä¢ Severity 
‚Ä¢ Causal relationship to study drug(s)  
‚Ä¢ Action taken  

Protocol VX14- 661-111, Version  4.0 Page 58 of 69 
Vertex Pharmaceuticals Incorporated   ‚Ä¢ Outcome  
‚Ä¢ Concomitant medication or other treatment given  
‚Ä¢ Indication of dose limiting toxicity  
[IP_ADDRESS] Adverse Event Severity  
The investigator will determine and record the severity of all serious and non-serious AEs. The 
guidance available at  the following website will be consulted: Common Terminology Criteria for 
Adverse Events (CTCAE), Version 4.0, Cancer Therapy Evaluation Program, http://ctep.cancer. gov/protocolDevelopment/electronic_applications/ctc.htm  (Accessed February 
2015). AEs of CTCAE Grades  4 and 5 will be documented as ‚Äúlife- threatening.‚Äù In considering 
the severity of an AE in a pediatric subject, the investigator will consider that referen ce ranges 
for pediatric clinical laboratory parameters may differ from those given in the CTCAE. The severity of an AE that does not appear in the CTCAE will be determined according to the definitions in Table 13 -1. 
Table 13-1 Grading of AE Severity  
Classification  Definition  
Mild (Grade  1) Mild level of discomfort and does not interfere with regular activities 
Moderate (Grade  2) Moderate level of discomfort and significantly interferes with regular activities  
Severe (Grade  3) Significant level of discomfort and prevents regular activities  
Life-threatening (Grade  4) Any adverse drug experience that places the subject, in the view of the investigator, 
at immediate risk of death  
AE: adverse event.  
[IP_ADDRESS] Adverse Event Causality  
Every effort will be made by [CONTACT_63398], if any, to th e 
study drug(s). Causality will be classified using the categories presented in Table 13-2. 
Table 13-[ADDRESS_1153750] been ruled out, 
and/or the event re -appeared on re -exposure to the investigational study drug.  
Possibly related  There is an association between the event and the administration of the 
investigational s tudy drug and there is a plausible mechanism for the event to be 
related to investigational study drug, but there may also be alternative etiology, such 
as characteristics of the subject‚Äôs clinical status or underlying disease.  
Unlikely related  The event is unlikely to be related to the investigational study drug and likely to be 
related to factors other than investigational study drug.  
Not related  The event is related to an etiology other than the investigational study drug (the 
alternative etiology will be documented in the study subject's medical record).  
AE: adverse event.  
[IP_ADDRESS] Study Drug Action Taken 

Protocol VX14- 661-111, Version  4.[ADDRESS_1153751] to an AE 
Classification  Definition  
Dose not changed  Study drug dose not changed in response to an AE  
Dose reduced  Study drug dose reduced in response to an AE  
Drug interrupted  Study drug administration interrupted in response to an AE  
Drug withdrawn  Study drug administration permanently discontinued in response to an AE  
Not applicable  Action taken regarding study drug administration does not apply.  
‚ÄúNot applicable‚Äù will be used in circumstances such as when the investigational 
treatment had been completed before the AE began and no opportunity to decide 
whether to contin ue, interrupt, or withdraw treatment is possible.  
AE: adverse event.  
[IP_ADDRESS] Adverse Event Outcome 
An AE will be followed until the investigator has determined and provided the final outcome. 
The outcome will be classified according to the categories shown in Table 13-4. 
Table 13-4 Classifications for Outcome of an AE 
Classification  Definition  
Recovered/Resolved  Resolution of an AE with no residual signs or symptoms  
Recovered/ Resolved 
With Sequelae  Resolution of an AE with residual signs or symptoms  
Not Recovered/Not 
Resolved (Continuing)  Either incomplete improvement or no improvement of an AE, such that it remains 
ongoing 
Fatal Outcome of an AE is death. ‚ÄúFatal‚Äù will be used when death is at least possibly 
related to the AE.  
Unknown  Outcome of an AE is not known (e.g., a subject lost to follow -up) 
AE: adverse event.  
[IP_ADDRESS] Treatment Given  
The investigator ensures adequate medical care is provided to subjects for any AEs, including 
clinically significant laboratory values related to study drug. In addition, the investigator will describe whether any treatment was given for the AE. ‚ÄúYes‚Äù is used if any treatment was given in response to an AE, and may include treatments such as other medications, hospi[INVESTIGATOR_059], surgery, or physical therapy. ‚ÄúNo‚Äù indicates the absence of any kind of treatment for an AE. 
13.1.2 Serious Adverse Events  
[IP_ADDRESS] Definition of a Seri ous Adverse Event  
An SAE is any AE that meets any of the following outcomes:  
‚Ä¢ Fatal (death, regardless of cause, that occurs during participation in the study or occurs after 
participation in the study and is suspected of being a delayed toxicity due to adm inistration of 
the study drug) 
‚Ä¢ Life-threatening, such that the subject was at immediate risk of death from the reaction as it 
occurred  

Protocol VX14- 661-111, Version  4.0 Page 60 of 69 
Vertex Pharmaceuticals Incorporated   ‚Ä¢ Inpatient hospi[INVESTIGATOR_318] 
‚Ä¢ Persistent or significant disability/incapacity (disability  is defined as a substantial disruption 
of a person's ability to conduct normal life functions) 
‚Ä¢ Congenital anomaly or birth defect 
‚Ä¢ Important medical event that, based upon appropriate medical judgment, may jeopardize the 
subject or may require medical or s urgical intervention to prevent 1 of the outcomes listed 
above (e.g., an allergic bronchospasm requiring intensive treatment in an emergency room or at home) 
If a subject has a hospi[INVESTIGATOR_29918] (e.g. surgery) for an event or condition that occurred before the subject signed the ICF, and the hospi[INVESTIGATOR_94250], the hospi[INVESTIGATOR_139356], unless an AE caused the hospi[INVESTIGATOR_139357]. In addition, hospi[INVESTIGATOR_94253] (e.g., social hospi[INVESTIGATOR_8933]) should not be considered to indicate an SAE. 
Clarification will be made between the terms ‚Äúserious‚Äù and ‚Äúsevere,‚Äù because they are not 
synonymous. The term ‚Äúsevere‚Äù is often used to describe the intensity (severity) of a specific 
event, as in mild, moderate, or severe myocardial infarction. The event itself, however, may be of relatively minor medical significance, such as a severe headache. This is not the same as ‚Äúserious,‚Äù which is based on subject/event outcome or action described above, and is usually associated with events that pose a threat to a subject's life or functioning. Seriousness, not severity, serves as a guide for defining expedited regulatory reporting obligations. 
[IP_ADDRESS] Documentation of Serious Adverse Events  
All SAEs that occur after obtaining informed consent and assent (where applicable) through the 
Safety Follow -up Visit, regardless of causality, will be reported by [CONTACT_306031]. In addition, all SAEs that occur after the Safety Follow- up Visit and are considered related 
to study drug(s) will be reported to Vertex GPS within 24  hours. 
SAEs will be recorded on the Vertex Organized Safety Information Collection Form (hereafter referred to as the ‚ÄúSAE Form‚Äù) using a recognized medical term or diagnosis that accurately reflects the event. SAEs will be assessed by [CONTACT_831249](s) and possible etiologies. On the Clinical Trials SAE Form, relationship to study drug(s) will be assessed only as related (includes possibly related) or not related (includes unlikely related), and severity ass essment will not be required. For the purposes of study 
analysis, if the event has not resolved at the end of the study reporting period, it will be documented as ongoing. For purposes of regulatory safety monitoring, the investigator is required to follow the event to resolution and report to Vertex the outcome of the event using the Vertex Clinical Trials SAE Form.  
[IP_ADDRESS] Reporting Serious Adverse Events  
The investigator is responsible for notifying the sponsor within 24 hours of identifying an SAE, regardless o f the presumed relationship to the investigational study drug. The Vertex Clinical 
Trial SAE Form will be completed for new/initial events as well as to report follow -up 

Protocol VX14- 661-111, Version  4.0 Page 62 of 69 
Vertex Pharmaceuticals Incorporated   will be made before the implementation of any changes. Any departures from protocol will be 
fully documented in the source documentation and in a protocol deviation log.  
13.2.4 Access to Records  
The investigator will make the office and/or hospi[INVESTIGATOR_168790]. The records will also be available for direct inspection, verification, and copy ing, as 
required by [CONTACT_774], by [CONTACT_775] (FDA and others). The investigator will comply with applicable privacy and security laws for use and disclosure of information related to the research set forth in this protocol.  
13.2.[ADDRESS_1153752] numbers. As required by [CONTACT_17926], the investigator will allow Vertex and/or its representatives access to all pertinent medical records to allow for the verification of data gathered in the eCRFs/SAE Forms and the review of the data collection process. The FDA (or other regulatory authority) may also request a ccess to all study 
records, including source documentation, for inspection. 
As applicable, in accordance with the Health Insurance Portability and Accountability Act 
(HIPAA) and associated privacy regulations, a subject authorization to use personally identifiable health information may be required from each subject before research activities begin. This authorization document will clearly specify which parties will have access to a subject's personal health information, for what purpose, and for how long. 
13.2.[ADDRESS_1153753] Retention  
The investigator will maintain all study records according to ICH  GCP guidelines and/or 
applicable local regulatory requirement(s), whichever is longest, as described in the Clinical 
Trial Agreement. If the investigator withdraws from the responsibility of keepi[INVESTIGATOR_94255], custody will be transferred to a person willing to accept the responsibility and Vertex will be notified.  
13.2.7 Study Termination 
At any time, Vertex may terminate this study in its entirety or may terminate this stud y at any 
particular site. In addition, for reasonable cause, either the investigators or their IRBs may terminate the study at their center.  
Conditions that may lead to reasonable cause and warrant termination include, but are not limited 
to: 
‚Ä¢ Subject or investigator noncompliance 
‚Ä¢ Unsatisfactory subject enrollment 
‚Ä¢ Lack of adherence to protocol procedures 
‚Ä¢ Lack of evaluable and/or complete data  
‚Ä¢ Potentially unacceptable risk to study subjects  
‚Ä¢ Decision to modify drug development plan 

Protocol VX14- 661-111, Version  4.0 Page 63 of 69 
Vertex Pharmaceuticals Incorporated   ‚Ä¢ Decision by [CONTACT_155434].  
13.[ADDRESS_1153754] will be entered into an eCRF by [CONTACT_94326] a secure, validated web -based electronic data captur e (EDC) application. Vertex 
will have read -only access to site- entered clinical data in the EDC application.  
Instances of missing, discrepant, or uninterpretable data will be queried with the investigator for resolution. Any changes to study data will be made to the eCRF and documented in an audit trail, which will be maintained within the clinical database.  
13.4 Monitoring  
Monitoring and auditing procedures developed or approved by [CONTACT_139417]. On- site checking of the eCRFs/SAE Forms for completeness and 
clarity, cross -checking with source documents, and clarification of administrative matters will be 
performed.  
The study will be monitored by [CONTACT_139411]. Monitoring will be done by [CONTACT_782] a repre sentative of Vertex, or designee (study site monitor), who will review the 
eCRFs/SAE Forms and source documents. The study site monitor will ensure that the investigation is conducted according to the protocol design and regulatory requirements. 
13.[ADDRESS_1153755]. It is the investigator's responsibility 
to ensure the accuracy, completeness, clarity, and timeliness of the data reported in the subject's 
eCRF. Source documentation supporting the eCRF data will indicate the subject's participation in the study and will document the dates and details of study procedures, AEs, other observations, and subject status. 
The investigator, or designated representative, will complete the eCRF as soon as possible after 
information is c ollected. 
The audit trail entry will show the user's identification information and the date and time of any correction. The investigator will provide formal approval of all the information in the eCRFs, including any changes made to the eCRFs, to endorse the final submitted data for the subjects for whom the investigator is responsible. 
Vertex will retain the eCRF data  and corresponding audit trails. A copy of the final archival 
eCRF in the form of a CD or other electronic media will be placed in the inves tigator's study  file. 

Protocol VX14- 661-111, Version  4.0 Page 65 of 69 
Vertex Pharmaceuticals Incorporated   14 REFERENCES  
 
 
1  FDA Office of Orphan Products Development (OOPD). Available from: 
http://www.fda.gov/ForIndustry/Developi[INVESTIGATOR_139360]/default.
htm. Accessed 18 February 2015. 
2  The Committee for Orphan Medicinal Products (COMP). Availabl e from: 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000263.jsp&murl=menus/about_us/about_us.jsp&mid=WC0b01ac0580028e30. Accessed 18 February 2015 
3
 Cystic Fibrosis Foundation Web Site [Internet]. Available from: http://www.cff.org/AboutCF/ . Accessed 18 February  2015. 
4
 Kriendler JL. Cystic fibrosis: exploiting its genetic basis in the hunt for new therapi[INVESTIGATOR_014]. Pharmacol Ther. 2010;125:219-29. 
5 Cystic Fibrosis Foundation. Cystic Fibrosis Foundation Patient Registry 2009 Annual 
Data Report. Bethesda (MD) : 2011.
 
[ADDRESS_1153756]. State of progress in treating cystic fibrosis respi[INVESTIGATOR_3765]. BMC Med. 2012:10(1):88. 
7  Cystic Fibrosis Foundation. Cystic Fibrosis Foundation Patient Registry: 2012 Annual 
Data Report. Bethesda (MD): 2013. 
8  European Cystic Fibrosis Society. ECFS Patient Registry: 2010 Annual Report. Karup, 
Denmark: 2014. 
9  Cystic Fibrosis Canada. The Canadian Cystic Fibrosis Registry: 2012 Annual Report. 
Toronto, Canada: 2014. 
10  Cystic Fibrosis Australia. Cystic Fibrosis in A ustralia 2012: 15th Annual Report From 
the Australian Cystic Fibrosis Data Registry. Baulkham Hills, Australia: 2013.  
[ADDRESS_1153757] cystic fibrosis. Cell. 1990;63:827-34. 
12 Dalemans W, Barbry P, Champi[INVESTIGATOR_139362] G, Jallat S, Dott K, Dreyer D, et al. Altered chloride 
ion channel kinetics associated with the delta F508 cystic fibrosis mutation. Nature. 1991;354:526-8. 
13  Quinton PM. Cystic fibrosis: impaired bicarbonate secretion and mucoviscidosis. Lancet 
2008;372:416-7. 
14 Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med. 2005;352:1992-2001. 
[ADDRESS_1153758] surface pH impairs bacterial killing in the porcine 
cystic fibrosis lung. Nature 2012;487:109-113. 

Protocol VX14- 661-111, Version  4.0 Page 66 of 69 
Vertex Pharmaceuticals Incorporated    
16  Gelfond D, Changxing M, Semler J, Borowitz D. Intestinal pH and gastrointestinal transit 
profiles in cystic fibrosis patients measured by [CONTACT_93755]. Dig Dis Sci 
2013;58:2275-2281. 
17  Van Goor F, Hadida S, Grootenhuis P. Pharmacological rescue of mutant CFTR function 
for the treatment of cystic fibrosis. Top Med Chem. 2008;3:91-120. 
18 Vertex Pharmaceuticals Incorporated. Effects of VRT -893661 on CFTR- mediated 
chloride secretion in human bronchial epi[INVESTIGATOR_315428]. Report G016. Report date: 17 Feb 2010. 
19 Lukacs GL, Chang XB, Bear C, Kartner N, Mohamed A, Riordan JR, et. al. The delta 
F508 mutation decreases the stability of cystic fibrosis transmembrane conductance regulator in the plasma membrane. Determination of functional half- lives on transfected 
cells. J Biol Chem 1993;268:[ZIP_CODE]-[ZIP_CODE]. 
[ADDRESS_1153759] of 
VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med. 
2010;363:1991-2003. 
21 Vertex Pharmaceuticals Incorporated. VX -661 Investigator's Brochure. Version 7.0. 
Report date: 08 May  2015. 
22 Vertex Pharmaceuticals Incorporated. Ivacaftor (VX -770) Investigator's Brochure. 
Version 13.0, Addendum 1. Report date: 23 June 2016. 
23 Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. 
Standardisation of spi[INVESTIGATOR_038]. Eur Respir J. 2005;26:319-38. 
24 Rowe SM, Heltshe SL, Gonska T, Donaldson SH, Borowitz D, Gelfond D, et al. Clinical 
mechanism of the cystic fibrosi s transmembrane conductance regulator potentiator 
ivacaftor in G551D- mediated cystic fibrosis. Am J Respir Crit Care Med. 
2014;190(2):175‚Äì184. 
25  Couper RT, Corey M, Moore DJ, Fisher LJ, Forstner GG, Durie PR. Decline of exocrine 
pancreatic function in cys tic fibrosis patients with pancreatic sufficiency. Pediatr Res. 
1992;32:179‚Äì182. 
26  Clarke LL, Harline MC. Dual role of CFTR in cAMP- stimulated HCO3 - secretion across 
murine duodenum. Am J Physiol. 1998;274:G718‚ÄìG726. 
[ADDRESS_1153760] J, Zhou R, Isenberg JI. Identification of 
transport abnormalities in duodenal mucosa and duodenal enterocytes from patients with cystic fibrosis. Gastroenterology. 2000;118:1051‚Äì1060. 
28  Gelfond D , Ma C, Semler J , Borowitz D . Intestinal pH and gastrointestinal transit profiles 
in cystic fibrosis patients measured by [CONTACT_93755]. Dig Dis Sci. 2013;58(8):2275-81. 
[ADDRESS_1153761] ance regulator gene mutations. J Pediatr. 1995;127:705-10. 

Protocol VX14- 661-111, Version  4.0 Page 67 of 69 
Vertex Pharmaceuticals Incorporated    
30 Rowe S, Accurso F, Clancy JP. Detection of cystic fibrosis transmembrane conductance 
regulator activity in early -phase clinical trials. Proc Am Thorac Soc. 2007;4:387-98. 
31  Hisert KB, Cooke JP, Garudathri J, Wu X, Pope C, Grogan B, et al. The 28th Annual 
North American Cystic Fibrosis Conference, Georgia World Congress Center, Atlanta, 
Georgia, Conference Supplement: Volume: 49 DOI: 10.1002/ppul.v49.S38/issuetoc.  
32 Rosenstein BJ, Cutting GR. The diagnosis of cystic fibrosis: a consensus statement. 
Cystic Fibrosis Foundation Consensus Panel. J Pediatr. 1998;132(4):589-95. 
33  Hankinson JL, Odencrantz JR, Fedan KB. Spi[INVESTIGATOR_11825] a sample of 
the general US population. Am J Respir Crit Care Med. 1999;159:179-87. 
34 Levey AS, Bosch JP, Breyer Lewis J, Greene T, Rogers N, Roth D. A more accurate 
method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med. 1999;130:461-70. 
35 Levey AS, C oresh J, Greene T, Stevens LA, Zhang Y, Hendriksen S, et al. Using 
standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145:247-54. 

Protocol VX14- 661-111, Version  4.0 Page 69 of 69 
Vertex Pharmaceuticals Incorporated   15.2 Investigator Signature [CONTACT_168805] #:  VX14-661-111 Version #:  4.0 Version Date  19 Sep 2016 
Study Title: A Phase 2, Randomized, Double -blind, Placebo -controlled, Parallel -group, 
Exploratory Study to Evaluate Effects of VX-[ADDRESS_1153762] the study according to its 
terms. I understand that all information concerning VX-661/ivacaftor and this protocol supplied to me by [CONTACT_139369] (Vertex) is confidential.  
 
 
Printed Name    
[CONTACT_155436] 
  
